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Stent placement for renal 
artery stenosis is reported to 
benefit some - but not all -
patients. This thesis aimed to 
investigate the parameters that 
determine vessel patency and 
clinical outcome of stent 
placement for renal artery 
stenosis. 
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INTRODUCTION 
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Obstruction of the renal arteries (renal artery stenosis, RAS) is a frequent entity with 
reported incidence of up to 53% in autopsy studies in unselected subjects.' RAS most 
often occurs in the context of systemic atherosclerosis and is then associated with 
plaque accumulation in the intimal layer of the renal artery wall. Less frequently, RAS 
may be associated with other diseases such as fibromuscular dysplasia, Takayasu's 
arteritis and neurofibromatosis, or with aortic coarctation.'" 
In many vascular territories without abundant collateral circulation, interruption of the 
supply of oxygen to the target tissue because of arterial stenosis causes symptoms of 
ischemic pain. In RAS, however, ischemic pain is not a prominent feature. RAS may 
present clinically with systemic hypertension, renal functional impairment but more 
often, RAS remains asymptomatic. In asymptomatic patients RAS is often found 
incidentally whenever angiograms are made for other purposes. It is open to debate 
whether patients with asymptomatic RAS should undergo revascularization of the renal 
artery. It has been argued, e.g .. that the disease is progressive in severity over time'" 
and that revascularization is indicated to prevent the future development of end-stage 
renal failure.' On the other hand, it is at present unknown whether RAS, if left untreated 
in these asymptomatic patients, will truly lead to clinical symptoms that make 
prophylactic revascularization worthwhile. 
Patients with symptomatic RAS are nowadays commonly treated by revascularization of 
the obstructed artery. Aside from surgical revascularization, RAS may be managed 
percutaneously by means of balloonangioplasty or stent placement. Although promising 
results especially of stent placement have been claimed with regard to renal artery 
patency and clinical outcome, some topics require further clarification. First, long-term 
vessel patency after renal artery stent placement is not always sustained, with reported 
restenosis in up to 39% of the patients at 8 months of follow-up.' Second, even in the 
presence of successful revascularization, clinical benefit of stent placement is obtained in 
only part of the patient popUlation that is treated. For the treatment of hypertension, 
reported benefit rates range from 39-78% of the patients after stent placement."" 
Likewise, renal functional improvement after stent placement has been reported in 
20-76% of the patients who were treated with this aim."'" 
It is clear, therefore, that additional data are required on the parameters that determine 
vessel patency and the clinical outcome after stent placement of RAS. Potential causes of 
restenosis after stent placement in coronary and femoropopliteal arteries may include 
inadequate stent deployment at the time of stent placement, neointimal tissue 
proliferation in the stent or at the stent edges, and stent recoil during follow-up.,,·18 To 
study vessel patency in greater detail. we propose the use of intravascular ultrasound 
(IVUS). IVUS provides high spatial-resolution tomographic information of the vessel wall 
(instead of the more limited information on the lumen diameter provided by 
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angiography), and can thus be used to accurately document the changes in the treated 
vessel segment that occur over time. 
Assessment of the clinical effect of stent placement for RAS is hampered by the absence 
of uniform definitions of 'clinical success'. Furthermore, it is generally difficult to study 
the effect of stent placement on the function of the treated kidney in isolation, because 
the conventional measures to assess renal function (i.e., serum creatinine, Cockroft 
clearance) reflect the combined functions of the treated and contralateral kidneys 
together. To obtain information on the effect of stent placement on the treated kidney 
per se one needs to measure single-kidney function over time. 
Finally, it is currently insufficiently known which parameters are predictive for a 
long-term favorable clinical outcome. Such predictors, if available, would be useful to 
help select those patients who would clinically benefit from stent placement. 
AIM AND OUTLINE OF THIS THESIS 
The aim of this work was to provide more insight in some of the questions raised above. 
In Chapter 2, the natural history of incidentally found RAS in patients with peripheral 
vascular disease is assessed, particularly with regard to the development of end-stage 
renal failure. This information may answer the question whether prophylactic 
revascularization in asymptomatic patients is a worthwhile procedure. Chapter 3 
presents a review and meta-analysis of the literature on stent placement and balloon 
angioplasty for RAS. The two treatment modalities are compared with regard to the 
vessel patency and clinical outcome. Chapter 4 describes the IVUS findings that 
characterize normal and diseased renal arteries in an in vitro set-up as a prelude to the 
in vivo use of IVUS in patients. Chapter 5 addresses the morphology of RAS as seen with 
IVUS in symptomatic patients. This information may be helpful to understand the 
mechanisms responsible for vessel behavior after stent placement and at follow-up. 
Chapter 6 reports on the additional information that may be provided by IVUS at the 
time of renal artery stent placement, which may optimize the technical aspects of stent 
deployment. Chapter 7 describes the differences in the behavior of stents in the renal 
and femoropopliteal artery at follow-up. The changes in the stented renal artery that are 
responsible for late lumen loss one year following stent placement are presented in 
Chapter 8. In Chapter 9 we studied the effect of stent placement on the function of the 
treated kidney. We performed serial single-kidney function measurements of the treated 
and contralateral kidneys separately. To identify those patients who will respond 
favorably to renal artery stent placement, Chapter 10 describes a regression analysis to 
identify pre-intervention parameters predictive for one-year clinical outcome of renal 
artery stent placement. Finally, Chapter 11 and 12 present the summary and 
conclusions of this thesis, together with recommendations for the clinical management 
of asymptomatic and symptomatic RAS and suggestions for further studies. 
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Renal artery stenosis (RAS) is 
frequently encountered as an 
incidental finding in peripheral 
vascular disease. To decide 
whether revascularization is 
necessary to prevent end-stage 
renal failure, patients with 
asymptomatic RAS were studied 
during 8-10 years of follow-up. 
None of the 126 patients with 
asymptomatic RAS developed 
end-stage renal failure or 
needed dialysis. Therefore, it 
seems that there is no clear 
indication for revascularization 
of RAS in these patients. 
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Should incidentally found atherosclerotic renal artery stenosis (RAS) be treated? This 
question frequently arises whenever RAS is unexpectedly encountered during 
examinations made for other purposes, e.g. during pre·operative angiography performed 
for peripheral artery disease. 
There are arguments that favor treatment. Atherosclerotic RAS is a recognized cause of 
ischemic nephropathy'" and has been shown to progress over time,'"' with a reported 
progression rate of the stenotic lesion of 7% per year.' RAS is associated with loss of 
renal function' and may cause end-stage renal failure with subsequent need for renal 
replacement therapy also in patients who initially not present with clear symptoms of 
renal artery stenosis. Observations in patients with end-stage renal failure showed that 
ischemic nephropathy was the cause of end-stage renal failure in 14% of patients >50 
years of age.' The main rationale for revascularizing incidentally found RAS seems 
therefore the prevention of end-stage renal failure.' Other reasons to treat include the 
prevention of the RAS-induced increase of cardiovascular morbidity and mortality.' 
On the other hand, there are also arguments not to treat: Why should one expose 
patients with incidentally found RAS to the potential complications, inconvenience and 
costs of revascularization treatment whenever there is no immediate need to do so? 
Furthermore, the true clinical significance of incidentally found RAS remains unclear. A 
reason not to treat may exist if patients die of other causes before the sequelae of RAS 
become clinically manifest. 
To decide whether or not there is a case for treatment of incidentally found RAS, 
objective data on the natural history of untreated incidental RAS are needed. There are, 
however, few such data available. Therefore we studied the 10-year natural history of 
patients with untreated incidentally found RAS and established whether these patients 
indeed developed end-stage renal failure and increased incidence of cardiovascular 
events compared to matched patients without RAS. 
METHODS 
In a retrospective study a cohort of consecutive patients who underwent digital 
subtraction angiography because of chronic ischemic peripheral artery disease from 
January 1989 to December 1991 was followed. This cohort was the oldest one available, 
given the fact that under Dutch law, hospitals are required to keep archives of all 
roentgenograms and medical records for a 10-year period. In our university hospital, 
angiograms made for peripheral artery disease include views of the abdominal aorta and 
the renal arteries. Patients in whom the angiogram did not allow proper assessment of 
the renal arteries were excluded from the analysis. Also excluded were patients who had 
received prior treatment for symptomatic RAS at the time of the angiographic 
examination. The study was approved by the local ethical review board. 
The angiograms were read by two independent observers blinded to the clinical 
information. The presence and severity of RAS was expressed in 10%-incremental steps 
starting at RAS of >50% lumen diameter stenosis. Differences between the two observers 
were solved by consensus. Accessory renal arteries with a stenosis were considered 
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significant whenever more than one-third of the renal mass was estimated to be supplied 
by the vessel. The stenoses were classified as atherosclerotic if they did not demonstrate 
the typical string-of-beads appearance. We then grouped the patients with significant 
RAS for comparison with the patients without RAS as controls. It soon became clear that 
patients with RAS had a different distribution of age and gender than patients without 
RAS (see Results). Because both these parameters are known to affect the relevant 
outcome parameters in this study, we formed the control group by obtaining a random 
selection of patients without RAS who were matched for age and gender (instead of 
taking the entire group without RAS). 
Baseline characteristics 
Six clinical variables were recorded at baseline (Le., the time of angiography): the 
Cockroft serum creatinine clearance as a measure of renal function; history of coronary 
artery disease (myocardial infarction or angina); history of cerebrovascular disease 
(stroke or transient ischemic attack); diabetes mellitus (present or absent); smoking 
history (ever or never); obesity (present or absent; defined as a body mass index> 25 
kg/m'). 
Fol/ow-up data 
Follow-up data were collected on patient survival and, where applicable, the cause of 
death. The occurrence of severe renal insufficiency with need for renal replacement 
therapy was recorded and, in addition, the incidence of cardiac and cerebrovascular 
(together, cardiovascular) events. Cardiac events included myocardial infarction, 
coronary angioplasty or coronary bypass surgery; cerebrovascular events included stroke 
and transient ischemic attack. It was recorded whenever renal artery revascularization 
was performed during follow-up. The follow-up data were retrieved by searching medical 
records and the electronic medical information system of the hospital; in case of 
insufficient follow-up data the patient's general practitioner was contacted for additional 
data. 
Statistical analysis 
Comparisons between groups on ordinate and qualitative variables were done with a 
Student's Hest or chi-squared test where appropriate. Survival curves for the two groups 
were constructed using Kaplan-Meier analysis and were tested for significant different 
survival with log-rank tests. Univariate and stepwise multivariate logistic regression 
analysis of survival was performed using the Cox proportional hazards model. Univariate 
regression analysis was performed using the clinical variables obtained at baseline, age, 
gender, and the angiographically scored severity of RAS. The variables that reached 
significance level in the univariate regression analysis were subsequently entered in the 
multivariate model. The variables were tested for significant covariant interaction with 
RAS. Model selection was performed by a backward selection procedure. All statistical 
tests were performed at the p=O.05 significance level using the SPSS software package, 
version 8.0. 
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RESULTS 
During the inclusion period angiograms were made in 593 consecutive patients with 
ischemic peripheral artery disease (Fig. 1). The renal arteries could be assessed in their 
entirety for possible RAS in 397 of these 593 angiograms. Of the 397 evaluable patients, 
11 were excluded because they had symptomatic RAS at the time of the angiographic 
examination with prior treatment. 
Patient population 
n=593 
I 
Angiograms available 
n=397 
Patients excluded 
n=11 
Angiograms used 
n=386 
RAS absent RAS present 
n=260 n=126 
mean age: 61.5 ± 11.6 Y mean age: 68.8 ± 9.8 Y 
70% males 66% males 
I 
Control group 
n=126 
Figure 1. Overview of the study population. 
The remaining 386 eligible patients were included in the analysis. RAS was present in 
126/386 patients (33%), which was unilateral in 88 patients (Fig. 2), bilateral in 32 
patients. Six patients had RAS and a single functioning kidney. Patients with RAS were, 
on average, older than those without RAS, with mean age ± standard deviation of 68.8 
years ± 9.8, versus patients without RAS, 61.5 years ± 11.6. Slightly less patients with 
RAS were male: 66% versus 70% males in patients without RAS. Accessory renal arteries 
were present in 84/386 patients (22%). 
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Figure 2. Angiogram showing left-sided renal artery stenosis. 
Control group and baseline parameters 
The control group consisted of 126 randomly selected patients without RAS who were 
matched for age and gender. At baseline, patients with RAS differed from controls on 
two parameters: significantly more patients with RAS had a history of coronary artery 
disease, p=O.OOl. Also, patients with RAS had a significantly lower Cockroft clearance, 
p=O.014 (Table 1). 
Morbidity and survival during long-term follow-up 
Data on morbidity and long-term survival are given in Table 2. We found that none of 
the 126 patients with RAS required renal replacement therapy during follow-up. One 
control patient without RAS developed end-stage renal failure necessitating 
hemodialysis. Five patients with RAS returned during follow-up because of symptomatic 
RAS and were treated with revascularization of the renal artery. None of these patients 
subsequently required renal replacement therapy. These results strongly indicate that 
incidentally found RAS does not lead to end-stage renal failure if left untreated. 
The incidence of cardiovascular events during follow-up did not differ between patients 
with RAS and the control group. Cardiac events occurred in 29% of patients with RAS 
versus in 22% of control patients. The incidence of cerebrovascular accidents was 18% for 
RAS and 11% for controls. 
19 
Chapter 2 
Table 1. Baseline parameters of the study population. 
RAS ~50% 
n 126 
Age (years) 68.8 ± 9.8 
Mates ("to) 66 
History of CAD (%) 52' 
History of eVA ('Yo) 20 
Diabetes mellitus (%) 22 
Ever smoked ("to) 73 
Obesity ("to) 32 
Cockroft Clearance (m1/min) 58.2 ± 22.3* 
n = Number of patients; CAD = COIOnaIY artery disease; 
CVA", Cerebrovascular accident; 
Controls 
126 
68.3 ± 9.5 
66 
31 
15 
21 
79 
40 
65.4 ± 23.7 
• to> statistically significant different from the control group, p<O.05; 
mean ± standard deviation indicated. 
Table 2. Follow-up data comparing patients with RAS :<!.50% and the control 
group. 
Renal replacement therapy ("to) 
Renal revascularizations ('Yo) 
Cardiac events ("to) 
Time to event 
(months) 
Cerebrovascular events ('Yo) 
Time to event 
(months) 
5UIvival 2 years ('Vo) 
6 years ("to) 
10 years (%) 
Mean ± standard deviation indicated. 
RAS::!:50% 
o 
4 
29 
54.8 ± 40.9 
18 
56.2 ± 40.7 
77 
55 
40 
Controls 
22 
64.7 ± 40.6 
11 
66.2 ± 40.6 
84 
61 
49 
The Kaplan-Meier survival curves for 10-year follow-up showed a difference in survival 
between patients with RAS and controls, although not significant (p=0.06; Fig. 3). 
Survival at 2, 6, and 10 years was 77%, 55%, 40% for RAS>50% and 84%, 61%, 49% for 
the control group (Table 2). 
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Figure 3. Ten·year survival of patients with RAS .:;..50% versus controls. 
Table 3. Known causes of death in the patient group with and without RAS. 
10 
patients 
at risk 
RAS Controls 
Cause (n0 52) (n-49) 
Cardiovascular events, n (%) 19 (37) 18 
General poor physical condition*. n (%) 23 (44) 16 
Neoplasms, n (%) 9 (17) !3 
Following surgeIJ' done for unrelated reason, n ('Yo) (2) 2 
n .. Number of patients; 
* including severe cardiac or pulmonary dysfunction, poorly controlled diabetes, 
gastro-intestinal bleeding. 
(37) 
(33) 
(27) 
(4) 
Analysis of the causes of death showed no significant difference between patients with 
RAS and controls (Table 3), The cause of death could be retrieved in 52/88 deceased 
patients with RAS and in 49/77 deceased control patients, Cardiovascular events were 
implicated as the direct cause of death in 19/52 patients with RAS (37%) and in 18/49 
control patients (37%). A major cause of death in both groups was "general poor physical 
condition" . 
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Table 4. Variables included in the multivariate regression analysis and their 
impact on long·term survival. 
Variable 
Mate gender 
Age>70y 
RAS ~ 60% 
History of CAD 
History of CNA 
Diabetes mellitus 
Obesity 
Cockroft Clearance < 50 mt/min 
CAD = Coronary artery disease; 
CI "" Confidence interval; 
Risk (95% el) 
ratio 
1.4 (1.00-2.13) 
1.8 (1.20·2.56) 
1.5 (1.04-2.10) 
1.1 (0.70-1.80) 
1.5 (1.02-2.43) 
1.5 (1.01-2.20) 
0.9 (0.58-1.29) 
2.0 (1.36-2.95) 
eVA = Cerebrovascular accident; 
NS = Not significant. 
p-value 
0,05 
0.004 
0,03 
NS 
0.04 
0.05 
NS 
<0,001 
Cox proportional hazards analysis showed that RAS of > 50% luminal diameter stenosis 
was not associated with increased mortality. However, more severe RAS of >60% stenosis 
proved to be a significant albeit weak predictor of increased mortality, p=0.03, with a 
relative risk of 1.5 (95%-confidence interval 1.04-2.10). Other statistically significant 
independent parameters of decreased survival in the multivariate model were: history of 
stroke, diabetes mellitus, age> 70 years, Cockroft clearance <50 mlfmin and male gender 
(Table 4). No significant covariant interactions between these parameters and RAS>60% 
were found. 
DISCUSSION 
The clinical importance of incidentally found RAS is at present uncertain. The question 
whether the disease leads to end-stage renal failure and increased cardiovascular 
morbidity and preventive intervention is indicated, was addressed in the present study. 
As a first finding, the present study confirmed the high prevalence of incidental RAS of 
> 50% stenosis in patients with peripheral vascular disease: 33% of 386 patients 
compared with 31% and 38% in two earlier series of 100 and 189 patients, 
respectively.'·lD RAS is more commonly present in peripheral artery disease than in 
coronary artery disease: the prevalence of incidental RAS was reported to be only 15% in 
1235 patients undergoing cardiac catheterization. ll 
In our study, incidental RAS was not associated with the development of end-stage renal 
failure. None of the 126 patients with untreated incidental RAS needed renal 
replacement therapy during up to 10 years of follow-up, despite the fact that at baseline 
these patients had, on average, a lower Cockroft clearance than controls (Table 1). 
Similar observations have been reported by Conlon et al. who found that only 1 of 188 
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patients with RAS (associated with coronary artery disease) developed end stage renal 
failure during 4 years of follow-up.' Conlon's study and ours strongly indicate that it is 
not necessary to revascularize incidental RAS to prevent future renal failure. This seems 
to contradict previous experience because angiographic and duplex ultrasound studies 
have shown that RAS, if left untreated, is a progressive disease that causes ischemic 
renal insufficiency and end-stage renal failure.'" However, patients who develop 
end-stage renal failure due to incidental RAS reported in those studies are probably a 
different population than patients who present with symptomatic peripheral 
atherosclerosis such as in the current patient group. 
At this point we wish to emphasize that we used the need for renal replacement therapy 
as the clinical endpoint, instead of the loss of renal mass that is more frequently used as 
a (substitute) endpoint. We believe, however, that 'need for renal replacement therapy' is 
the more relevant parameter, as for the individual this makes the difference between 
being 'a healthy person' or 'a patient'. 
Patients with RAS did not experience more cardiovascular events during follow-up than 
the control group. The cardiovascular mortality was also not increased. Considering these 
findings, there seems to be no rationale to revascularize incidental RAS with the aim to 
prevent cardiovascular morbidity and mortality. 
An additional finding in our study was that incidental RAS in peripheral artery disease 
was not associated with a significantly decreased 10-year survival. This was in contrast 
with the previously mentioned study of Conlon et al.', in which incidental RAS in 
coronary artery disease was associated with decreased 4-year survival compared to 
controls (65% vs. 89%, respectively). The 10-year survival in our study (40% for patients 
with RAS versus 49% for controls) was in accordance with the previously reported data of 
Hertzer. In the latter study the 10-year survival rate in 871 patients with peripheral 
vascular disease ranged from 30-50%." These data indicate that patients with peripheral 
vascular disease, in general, have a limited 10-year survival. 
In our study RAS > 60% proved to be a weak predictor for decreased survival. Subanalysis 
showed, that RAS > 60% was not associated with increased cardiovascular mortality but 
that such events occurred earlier during follow-up (52 ± 39.6 months versus 65 ± 40.6 
months for controls). This data suggest that incidental RAS is an expression of advanced 
atherosclerosis rather than a causal factor for cardiovascular morbidity. This might be 
illustrated by the borderline statistically significant difference in 10-year survival 
between the two groups. An additional argument to support this view is that at baseline, 
patients with RAS had more clinical symptoms of atherosclerosis, in particular, a history 
of coronary artery disease. 
Some limitations of our study should be considered. First, not all renal arteries were 
evaluable in the patients of the cohort. This may have introduced a selection bias in the 
(unlikely) event that non-visualization of the renal arteries was associated with the 
presence of RAS. However, we believe that in nearly all cases, non-visualization of the 
renal arteries was related to technical imaging factors. Second, many angiograms were in 
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the anterior-posterior projection view only. As a result, RAS may have been missed in 
some patients, who may then have been erroneously assigned to the control group. 
This bias would not interfere with the finding that RAS does not cause end-stage renal 
failure, but may have led to underestimation of the true prevalence of incidental RAS 
and have obscured potential differences between patients with RAS and controls. 
However, the prevalence of RAS in our study was similar to that found in earlier 
studies.9•10 Third, in retrospective study like this, it was impossible to obtain reliable 
blood pressure data. In this way, the effect of hypertension on the major events in this 
study could not be determined. However, the incidences of cardiac and cerebrovascular 
events, which are directly related to hypertension, were not statistically significant 
different for patients with and without RAS. Therefore, we believe that renovascular 
hypertension did not play a significant role in the present study. Fourth, despite 
extensive efforts some follow-up data remained missing. Yet, overall we believe that our 
data are sufficiently complete and do not suffer from systematic bias. 
In conclusion, our observations showed that untreated incidental RAS does not cause 
end-stage renal failure and is unlikely to cause increased cardiovascular morbidity and 
mortality. The current trend towards aggressive interventional treatment of incidentally 
found RAS needs careful re-appraisal. 
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In 1978 percutaneous transluminal renal angioplasty (PTRA) was introduced by Griintzig 
et al. l as an alternative for surgical treatment for renal artery stenosis. In subsequent 
years numerous studies reported the beneficial effect of PTRA on the management of 
renovascular hypertension and renal function.' Studies showed that PTRA is an attractive 
alternative with lower complication rates than surgical intervention. Since then PTRA 
has become widely accepted for treating renal artery stenosis, although a restenosis rate 
of 27-100% at 6-12 months follow-up has been acknowledged as a major limitation of the 
procedure.3.< Besides, in patients treated for atherosclerotic renal artery stenosis the 
effects on blood pressure were disappointing, but in patients suffering from renal artery 
stenosis due to fibromuscular dysplasia, PTRA proved to be successful with cure rates for 
hypertension of 22% versus 83%, respectively.' 
With the introduction of self-expanding and balloon-expandable metallic stents a 
new treatment modality became available to treat atherosclerotic renal artery stenosis 
that might overcome poor angioplasty results, immediate post-angioplasty complications 
and restenosis. Since the first studies on renal artery stenting in 1991,'·' several case 
series established the successful placement of stents in renal artery stenosis. This 
overview presents the findings of these series with regard to the safety and efficacy of 
the procedure and compared the findings with PTRA. 
METHODS 
A literature review was performed of studies dealing with renal artery stenting identified 
by a Medline search of the English-language medical literature up to August 1998. To 
avoid double counting, data from the most recently published articles from a particular 
institution were included, thereby ignoring the possible additional information in 
previously published work. From the 14 series identified, '·19 when available, the following 
data were extracted: 
1. Patient selection criteria 
2. Lesion characteristics 
3. Procedure 
4. Anti-thrombotic therapy 
5. Initial technical success 
6. Complications 
7. Duration of follow-up 
8. Clinical results 
9. Restenosis rate. 
Data extraction was performed by the first author (TCL) and verified by the co-author 
(EJG). Discrepancies in the extracted data were solved by these authors examining the 
articles simultaneously. 
The variables initial technical success rate, complication rate, clinical results and 
restenosis rate across the studies were tested for homogeneity using the chi-squared test 
(two-sided, 0: = 0.05). As these variables were not uniformly defined or measured under 
identical conditions a random-effects model. as described by Laird and Mosteller" in 
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1990, was used to combine the data. Mean age of patients, mean number of stents per 
artery and mean period of clinical and angiographic follow· up across studies were 
combined with use of weighted means. 
Relationship between categorical variables was demonstrated in contingency tables using 
the chi-squared test; for continuous variables Pearson's correlation coefficient was 
calculated using SPSS for Windows (version 7.0). Correlation coefficients were determined 
between 'age' and the following variables: lesion characteristics, stents per artery, initial 
technical success, complication rate, percentage cured or improved for hypertension or 
renal function, and restenosis rates. Correlation coefficients were considered worth 
mentioning in case of r values >0.50. A P value <0.05 was considered statistically 
significant (two-sided). 
Finally, the results of stent placement in patients with renal artery stenosis were 
compared with the results of PTRA in a similar patient group. Because the majority of 
stent studies was published from January 1995 to August 1998, studies dealing with 
PTRA for renal artery stenosis published in the same period were included to obtain 
contemporary controlsYt-2' The following parameters were compared between the stent 
studies and the PTRA studies: indication for intervention, initial technical success, 
complication rate, percentage cured or improved for hypertension or renal function, and 
restenosis rate. Comparison was performed in contingency tables using the chi-squared 
test (two-sided, a- 0.05) to test for statistical significance. 
RESULTS 
Pooled data of all patients undergoing renal artery stent placement (n=678) are listed in 
Tables 1 and 2. 
Patient selection criteria 
Patients included in the survey had a mean age of 66 years ranging from 55' to 70 
years. ",17 The criteria used for selecting patients for stent placement varied widely. 
Clinical indication for intervention was a combination of hypertension and renal failure 
in all but four reports,IO,15,17,18 The number of patients treated for hypertension was 
higher than for renal function impairment (536 vs, 344, respectively), In 10 of the 
studies stent placement was performed after initial or late PTRA failure.'·9,1l,1l'17 In two 
studies stent placement was the primary intervention ",19 and the remaining two studies 
used stent placement as primary or secondary intervention,IO,18 The angiographic 
definition of a significant stenosis ranged from ~40% to >70% lumen diameter reduction, 
Lesion characteristics 
On angiography a distinction was made between ostial and truncal lesions, and lesions 
due to atherosclerosis or fibromuscular dysplasia, Ostial lesions were defined as stenoses 
of the renal artery within 2 mm18, 4 mm17 or 5 mmlO,1l of the aortic lumen, In one study 
an ostial lesion was defined as a stenosis without a nondiseased renal artery segment 
between the lesion and the aorta." More ostial lesions were treated than truncal lesions 
(371/139). In seven reports either ostial or truncal lesions were treated, In three studies 
only ostial lesions were treated"IO,1l and in one study only truncal lesions were involved,' 
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In the remaining three studies the location of the lesion was not mentioned.",17,l9 Renal 
artery stenoses were atherosclerotic in origin in the majority of cases. Incidentally, 
patients were included with renal artery stenosis due to fibromuscular dysplasia (n=6), 
Takayasu arteritis (n=2) and/or post-transplant stenosis (n=4).,,7,9,11,14 
Table 1. Patient's characteristics, type of stents used and initial angiographic success foUowing renal artery stent 
placement. 
Patients Stent Initial angiographic success 
Compli· 
Success cations· 
Patients Age Arteries Indication location Stents per Stent type Criterion % narteries 
Author n y"", n lITjRF Ost/l'runc artelY n %DS arteries (%) 
Wilms6 11 60 12 10/1 6/6 1,25 WaUstent <20 83 3 (25) 
Kuhn1 10 56 10 9/10 0/10 1.40 Strecker <20 80 4 (40) 
Reess 28 66 28 28/14 28/0 1.11 Patmaz <30 96 5 (18) 
Hennequint 21 55 21 21/6 7/14 1.19 WaUstent <30 100 4 (19) 
van de Ven10 24 67 28 24/0 28/0 1.14 Patmaz <10 100 3 (11) 
Henryll 59 65 64 59/10 34/30 1.00 Palmaz <20 100 2 (3) 
lannonell 63 70 83 63/29 51/32 1.00 Patron <30 99 11 (13) 
Btumll 68 60 74 68/20 74/0 1.03 Palmaz <50 100 0(0) 
Boisctairu 33 63 35 33/17 19/16 1.00 Palmaz <30 100 6 (17) 
Harden'S 32 67 32 0/32 NM 1.03 Patmn <10 100 1(3) 
White16 100 67 133 100/44 107/26 1.12 Palmaz <30 99 2 (2) 
Rundbacku 45 70 54 0/45 NM NM Palmaz <30 94 5 (9) 
Shannonll 21 63 23 0/21 17/5 1.09 Patmaz NM 100 2 (9) 
Dorrosu 163 67 202 121/95 NM NM Palmaz <50 100 23 (11) 
Mean' 678' 66' 799' 536/344 371/139' 1.07 1 98 11 
95%CI 95·100 6·16 
n= number; Ost = Ostial; Tronc '" Truncal; HT = Hypertension; RF = Renal failure; %DS '" Percentage diameter stenosis; 
NM = Not mentioned: CI=Confidence interval. 
• Hematomas and puncture traumas excluded. 
t Mean based on Random-Effects Model, except where indicated as weighted mean or as totals. 
I Totals. 
J Weighted mean. 
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Table 2. Clinical and angiographic foHow-up of patients undergoing renal artery stent placement. 
CUnical foHow-up Angiographic follow-up 
Hypertension Renal function Restenosis 
Patients Arteries 
for Fonow- for Follow-
follow-up up Cured Improved Improved Stabilized fonow-up up Criterion 
Author % months % % % % % months % OS % 
Wilms6 100 7 30 40 0 0 58 7 NM 29 
Kuhn1 80 11 29 43 50 NM 100 7 >50 25 
Rees8 100 7 11 54 36 36 64 8 >50 39 
Hennequin' 100 32 14 86 17 50 95 29 >70 20 
van de Ven l (>' 92 6 68 5 36 64 82 6 >50 13 
Henrylt 92 14 19 57 20 NM NM 6 >50 9 
Iannonelll 86 10 4 35 36 45 83 11 >60 14' 
Blumll 100 27 16 62 NM NM 100 27 >50 11 
Boisctairl4 100 13 6 61 41 35 23 NP >50 NP 
Hardenu 100 6 NM NM 34 34 75 6 >50 13 
White" 100 6 NM NM 20 NM 60 9 >50 19 
Rundbacku NM 17 NM NM NM NM 52 13 >50 25 
Shannonl8' 100 9 NM NM 43 29 NM 9 >50 0 
Dorroslll 28 48 3 51 NM NM NP NM NM NP 
Mean' 91f 1611 20 49 30 38 "f 17'11 17 
95% Ci 4-37 16-83 22·39 25-51 12-23 
n '" number; % DS '" Percentage diameter stenosis; NM = Not mentioned; Np .. Not routinely performed; 
Cl=Confidence interval. 
~Primary and secondary stent placement. 
I Primary stent placement. 
I Duplex restenosis. 
I Mean based on Random-Effects Model, except where indicated as weighted mean. 
II Mean. 
OJ Weighted mean. 
t If number of patients for follow-up not reported, estimated from number of arteries for follow-up and vice versa_ 
If angiographic follow-up not reported, estimated from clinical follow-up. 
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Procedure 
In 11 studies the femoral approach was used for access; the brachial approach was used 
in the remaindeL 15,I6,19 Stent placement was preceded by predilatation or baUoon 
angioplasty in aU but one study,19 The reason for predilatation was given in two studies: 
in one study to decrease the inflation pressure required for stent expansion,' and in the 
second to ensure that fuU expansion of the lesion was possible,16 In one study the lesion 
was overdilated up to 120% of the original vessel size before stent placement.' The 
majority of studies (n=ll) did not describe the method used for vessel sizing (probably 
they used visual estimation). In the remaining three studies digital angiographic analysis 
was used.",I1,16 In 11 studies the Palmaz stent was used; two studies reported the use of 
WaUstents'" and in one study the Strecker stent was used,' Overdilatation of the stent 
was performed in four studies up to 110%,,16 or 120%13 of the original vessel size or 
0,5·1,0 mm larger than the original vessel.' The reason for this overdilation was reported 
as "to compensate for neointimal growth and to prevent the stent from migrating",' For 
ostial lesions a slight protrusion of the stent into the aorta was recommended in five 
studies, 1O,1I,13,",18 In addition, in one study the part of the stent protruding into the aorta 
was reshaped with the use of a larger baUoon." 
Anti-thrombotic therapy 
Prophylaxis against thrombosis during the procedure was used in aU series, but the 
regimens varied. These included a bolus 2.000-10,000 IU of heparin"",'·lI,13,16 a bolus of 
heparin (1,000-5,000 IU) and nitroglycerine (100-400 I'g),8.1<,I7,18 or a combination of 75 
mg dipyridamole, 325 mg aspirin.and mannitol (10% Lv,), 19 
Six studies used intravenous heparin for anticoagulation the first days after renal artery 
stent placement'.7",",13,,, titrated to obtain a normal partial thromboplastin time two to 
three times normal. The anticoagulation regimen at patients' discharge was changed to 
aspirin 100-300 mg/d,',9-I1 aspirin 660 mg/d and dipyridamole 150 mg/d,' aspirin 100 
mg/d or ticlopidine 250 mg/d,13 or warfarin," Other studies used aspirin 75-300 mg/d18 
or warfarin (INR 2,0-2.5, 1-3 months)16 only, or used a combination of aspirin, 
dipyridamole and warfarin. 19 Two studies did not. routinely use anticoagulation after 
renal artery stent placement',17 and two other studies did not report their 
anticoagulation regimen. 12,lS 
Initial technical success 
The initial technical success of the procedure reported was not significantly different 
among the studies, In the first two studies successful stent placement was achieved in 
83% and 80%, respectively,'" foUowed by success rates ranging from 94% to 100% in 
subsequent studies (Table 1), It should be noted, however, that the definitions for 
technical success ranged from <10% residual stenosislO,15 to <50% residual stenosis, 13,19 
Complications 
Of the complications encountered the most frequently reported were hematoma 
formation and puncture trauma (n=40), More severe complications in 71 of the 799 
treated arteries (9%) included renal failure (n=34; three fatal), segmental renal infarction 
(n=9), perinephric hematoma (n=9; two fatal), renal artery thrombosis or occlusion 
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(n=6), stent misplacement (n=5), proteinuria (n=2), sepsis (n=l), brachial artery 
occlusion (n=l), stent/vessel mismatch (n=l), cholesterol embolism to the lower 
extremities (n=l), dissection of the iliac artery (n=l) and brachial artery bleeding (n=l; 
fatal). The mean mortality rate related to the procedure was 1.2% (95% CI: 0-2.5). The 
mortality rate usually included deaths directly or indirectly related to the procedure 
within the first month after stent placement. '.12.15.18 In one study the mortality rate 
included a patient who died six months after stent placement due to rupture of a 
pseudoaneurysm caused by the intervention. I' One study did not mention the 
post-procedural period in which the mortality rate was calculated;" therefore this study 
was not included in the mortality rate. In addition, six other patients died, described as 
due to a cause not related to the procedure. The complication rate varied significantly 
across the studies (p<0.001) and was significantly lower in studies using Palmaz stents 
than those using other stent types (8% vs 25%; p<O.OOl); the combined complication 
rate was 11% (95% CI: 6-16; Table 1). 
Follow-up 
The clinical follow-up period ranged from six months l ,.I,.16 to 48 months;I' for 
angiographic follow-up six months was the shortest intervaV,·II.I' whilst the longest 
follow-up period was 29 months.' 
Clinical results 
The clinical effect of renal artery stent placement on blood pressure was expressed in 
terms of 'cure' and 'improvement', although both classifications were not uniformly 
defined. In most studies 'cure' was defined as a diastolic blood pressure of 90 mmHg or 
less without medication.6.M •II.I, Other definitions of 'cure' irle,uded blood pressure less 
than 160/95 mmHg!' blood pressure less than 160/95 mmHg without medication' and 
systolic blood pressure less than 160 mmHg and/or diastolic blood pressure less than 90 
mmHg without medication!' In addition, one study reported 'clinical success' as systolic 
blood pressure less than 160 mmHg and diastolic blood pressure less than 90 mmHg with 
the same or less medication. 16 Definitions used for improvement of hypertension varied 
widely and are summarized in Table 3. More uniform criteria were used to define the 
effect of renal artery stenting on renal function in terms of 'improvement', 'stabilization' 
and 'deterioration'. Renal function was considered improved when the serum creatinine 
values decreased more than 20%,1'·11.1'.11.1' more than 15%,·12.1' or more than 18 I'moljl." 
Renal function was considered stabilized when the change in serum creatinine values was 
less than the above-mentioned values and deteriorated when serum creatinine values 
increased with the above-mentioned values. In five studies no criteria for change in renal 
function were provided.6.,.,.13.16 
The percentage of patients cured from hypertension (20%; 95% CI: 4-37) was not uniform 
between the different studies (p<0.001; Table 2). The percentage of patients in whom 
hypertension improved as result of renal artery stenting was higher (49%; 95% CI: 16-83) 
and differed significantly between the studies (p<0.001). No report found a significant 
decrease in overall serum creatinine values after stent placement. Renal function in 
patients with renal failure was improved in 30% (95% CI: 22-39), and stabilized in 38% 
33 
Chapter 3 
(95% CI: 25-51). These results did not vary significantly across the studies (p.0.13 and 
0.11, respectively; Table 2). 
Table 3, Definitions used to describe improvement of blood pressure foHowing renal artery stent placement. 
Author Definition 
Wilms' Diastolic blood pressure ~15% decreased and> 90 mmHg but < 110 mmHg 
Kuhn' Decrease in systolic and diastolic blood pr-essure ~ 10 mmHg, the same or fewer medication 
Reese Diastolic blood pressure :>:15 mmHg decreased with the same or fewer medication or fewer medication 
or diastolic blood pressure ;;0:15% decreased and> 90 mmHg but < 110 mmHg and the same or fewer 
medication 
Hennequin9 Diastolic blood pressure <90 mmHg with the same or fewer medication or diastolic blood pressure 
~15% decreased and> 90 mmHg but < 110 mmHg and the same or fewer medication 
van de Ven10 Decrease of mean arterial pressure <':200/0 
lannoneu 
Boisclair14 
Diastolic blood pressure <':15% decreased with the same or fewer medication 
Diastolic blood pressure <90 mmHg and fewer medication or diastolic blood pressure >90 mmHg and 
>10 mmHg decrease with fewer medication 
Diastolic blood pressure of 91 to 110 mmHg and a <': 15% decrease or diastolic blood pressure of 91 to 
110 mmHg, a <':10% decrease and <':1 drug tess medication 
Diastolic blood pressure <90 mmHg or 90-110 mmHg, a :?15% decrease with the same or fewer 
medication 
Harden u NM 
White!6 Clinical success: systolic blood pressure <150 mmHg and diastolic blood pressure <90 mmHg with the 
same or fewer medication 
Rundback l1 NM 
Shannon!8 NM 
Dorros!' Systolic or diastolic blood pressure <': 10% or <': 15% decreased with the same medication or systolic or 
diastolic blood pressure remained the same or decreased <10% or <15% with fewer medication 
NM .. Not mentioned. 
Restenosis rate 
Angiographic follow-up was performed in all but three studies: in two studies follow-up 
angiography was not routinely performed 1<.19 and one study used duplex ultrasound for 
detection of restenosis. " The definitions used for restenosis were not uniform among the 
studies. The criterion of >50% diameter stenosis was used for restenosis in most studies. 
Incidentally, >60% stenosis" and >70% stenosis' were criteria for restenosis. Unclear, 
however, was whether the percentages were calculated at the stent site (local stenosis) 
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Table 4. Patient's characteristics and initial angiographic success following percutaneous transluminal renal 
angioplasty. 
Patients Initial angiographic su.ccess 
Patients A" Arteries Indication Location Criterion Success Complications" 
Author n YeaTS n HT/RF OstjTrunc %DS % arteries n arteries ('Yo) 
Karagiannis 21 62 65 76 62/27 NM <50 72 3 (4) 
Jensen 21 107 63 147 NM NM NM 82 8 (5) 
Eldrup-Jorgensen 2) 52 68 60 10/42 NM NM '2 3 (5) 
BonelU 14 
"0 64 252 NM 53/18' <30 82 56 (23) 
Von Knorring 21 38' 60 38 38/0 9/29 NM NH NM 
TulUs 26 41 65 52 41/0 29/23 ..;601 75 NM 
Baumgartner 1I 56 60 63 25/25 NM <60' NH NM 
Hoffman) 50 66 52 46/36 52/0 <30 58 , (18) 
Plouin 28 23 59 23 23/0 7/16 N11 NM 6 (26) 
Webster H 25 60 25 25/0 13/12 NM NM 3 (12) 
Meant 644 11 64' 778 ~ 270/130 II 1631269 ~ 77 13 
95%CI 68·86 6-19 
n= Number; Ost '"' Ostial; Trune '"' Truncal; HT = Hypertension; RF = Renal failure; %DS = Percentage diameter stenosis; 
NM = Not mentioned; CI=Confidence interval. 
., Hematomas and puncture traumas excluded. 
I Only patients with atherosclerotic renal artery stenosis analyzed. 
I Based on Duplex Ultrasound. 
I Mean based on Random·Effects Model, except where indicated as weighted mean or as totals. 
~ Totals. 
1 Weighted mean. 
or compared to the reference site (relative stenosis). This may cause considerable 
variation between the reviewed studies. The overall restenosis rate after renal artery 
stent placement, depending on the angiographic definition, was 17% (95% CI: 12-23) and 
ranged from 0%" to 39%' (p=0.04). 
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Table 5. Clinical and angiographic foHow-up of patients undergoing percutaneous transluminal renal angioplasty. 
CUnical follow-up Angiographic follow-up 
Hypertension Renal function Restenosis 
Patients Follow- Arteries 
for up for Follow-
foHow-up months Cured Improved Improved Stabilized follow-up up Criterion 
Author % % % % 'I. % months % DS % 
Karagiannis 21 ;8 ;0 19 52 22 50 NM NM NM NP 
Jensenu 78 12 12 ;0 NM NM 77 12 >75 9 
Eldrup- NM 28 NM NM NM NM NM NM NM NP 
JorgensenU 
BonelU2' NM 33 8 62 NM NM NM 22 >70 NP 
Von KnorringU 71 ;8 11 7; NM NM NM ;8 NM NM 
TulUsl6 35 28 11 33 50 ;0 35 2; >60 55 
BaumgartnerH 70 13 9 ;6 ;8 36 NM 13 >60'1' 28 
Hoffmanl ;9 21 2 6; 32 36 50 11 >50 27 
Plouinu 23 6 NM NM NM NM 100 6 >50 13 
WebsterU 25 NM NM NM NM NM 35 12 NM NM 
Meant 50' 22' 10 53 38 41 59' 191J1 26 
95% CI 7·14 42·63 25·51 35·48 11·42 
n = Number; % DS = Percentage diameter stenosis; NM '" Not mentionEld; NP "" Not standardly performed; 
CI '" Confidence interval. 
I Mean based on Random-Effects Model, except were indicated as mean or weighted mean. 
I Mean. 
J Weighted mean. 
II If number of patients for follow-up not reported, estimated from number of arteries for follow-up and vice versa. 
If clinical foUow-up not reported, estimated from angiographic follow-up. 
'1 Based on Duplex Ultrasound. 
Relationship between variables 
Calculation of correlation between variables showed that older patients had more ostial 
lesions (r~O.61; p~O.05), significantly less stents per artery (r~-O.65; p~O.02), and a 
significantly lower complication rate than younger patients (rc-O.56; pc O.04). Finally, 
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patients' age was significantly related with success rate for hypertension: the older the 
patient, the smaller the effect on blood pressure (r= -0.77; p=0.009). 
Comparison with PTRA 
Data on PTRA are given in Tables 4 and 5. The patient groups for stent placement and 
PTRA showed significant differences in indication for intervention and the location of 
the lesion involved. In the stent studies more patients with renal failure and more ostial 
lesions were included than in the PTRA studies (p<0.02 and p<O.OOl, respectively). The 
technical success rate was significantly higher after stent placement compared with PTRA 
alone (98'10 and 77'10, respectively; p<O.OOl). The complication rate was not significantly 
different between stent and PTRA alone (11'10 and 13'10, respectively; 0.2<p<0.3). The 
proportion of patients in whom hypertension was cured was significantly different (20'10 
after stent placement and 10'10 after PTRA; p<O.OOl); the proportion of patients with 
improvement of hypertension was very similar for both treatment strategies (49'10 and 
53'10, respectively; 0.1<p<0.2). The percentage of patients with improved renal function 
was significantly lower for stent placement than for PTRA (30'10 vs 38'10, respectively; 
p<O.OOl). Restenosis rates, however, were significantly lower after stent placement than 
after PTRA alone (17'10 and 26'10, respectively; p<O.OOl). 
DISCUSSION 
Review of 14 studies dealing with patients with hypertension and/or renal failure 
indicated that renal artery stent placement is an attractive treatment modality showing a 
high initial success rate (98'10) with an average restenosis rate of 17'10 at 17 months 
follow-up. At six to 48 months follow-up hypertension was cured in 20'10 of the patients 
and improved in 49'10. Renal function in the patients with impaired renal function was 
improved in 30'10 and stabilized in 38'10. 
In the early studies the majority of patients studied was included in order to assess the 
effects on blood pressure. Later studies assessed the effect on renal function in patients 
with renal failure regardless of the presence of hypertension."·t7·18 It is acknowledged 
that although the minority of patients with chronic renal failure has renovascular 
disease, intervention by PTRA or stenting in renal failure associated with renovascular 
disease seems worthwhile since a stenosis of the renal artery is one of the few 
correctable causes of renal failure. In most of the reviewed studies secondary renal artery 
stent placement was performed i.e. after initial or late failure of PTRA. In some studies, 
however, primary stent placement or combined primary or secondary stent placement 
was performed. Patients undergoing secondary stent placement after unsuccessful PTRA 
may have more severe renal artery disease and are therefore perhaps more difficult to 
treat with stent placement than patients undergoing primary stent placement. This 
phenomenon could have caused a selection bias and makes comparison between studies 
of technical and clinical results difficult. 
The majority of patients selected had atherosclerotic renal artery stenosis. According to 
the literature the outcome of PTRA for renal artery stenoses due to fibromuscular 
dysplasia appears to be much better than for atherosclerotic stenoses.' No conclusions 
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could be drawn about the value of stenting for fibromuscular dysplasia because these 
patients were much underrepresented in this review. 
Most investigators used the Palmaz stent; only three studies used other stent types.'·7., 
Clinical success and restenosis rates in these series did not substantially differ from those 
reported with Palmaz stents. Complication rates, however, were higher in the studies, 
which did not use Palmaz stents, but these results have to be interpreted with caution 
since only three studies used other stent types. In the studies using Wallstents'" 
problems were encountered with the stent visibility on fluoroscopy. This is of utmost 
importance for correct stent placement, especially when the selected stent is short. The 
femoral approach for access into the renal artery was commonly used in the reviewed 
studies and seems to be safer than the brachial 'approach which is illustrated by the case 
of the patient who died due to uncontrolled bleeding from a brachial puncture site. I' 
In the reviewed studies no specific relation could be found between the anti-thrombotic 
therapy used and the outcome and complications of the intervention. Anti-thrombotic 
therapy is warranted to prevent thrombosis, but at the same time significant bleeding 
complications should be avoided. 
Initial technical success of renal artery stenting was high, and concurred with success 
rates of stent placement in coronary arteries. lO•n However, the difference in angiographic 
definitions used for technical success made adequate comparison difficult. We ourselves 
used intravascular ultrasound following angiographically successful renal artery stent 
placement and found that intravascular ultrasound data warranted further increase of 
vessel dimensions in 33% of the patients studied." Future studies will learn whether 
renal artery stent placement guided by intravascular ultrasound is beneficial for the 
long-term outcome. 
The initial technical success rate of stent placement was consistently high (>80%). The 
complication rate encountered (11%) varied among the studies reviewed. The cause of 
the difference in complication rates between the studies (0% to 40%) remains 
speculative. The mortality rate due to renal artery stent placement was the same as 
previously reported following coronary artery stenting (1.2%)." 
Reviewing the results of renal artery stent placement for renovascular disease, it appears 
that there is no universally accepted reporting standard. Although all reports describe a 
decrease in systolic and diastolic blood pressure after stent placement, there is much 
variation between definitions for 'cure' and 'improvement' of hypertension. This aspect 
hampered adequate comparison between the different studies included and may explain 
the difference in clinical results achieved. In addition, the adjustment of 
anti-hypertensive drugs after stent placement was not sufficiently described and 
quantified. The actual effect of stent placement on blood pressure in these uncontrolled 
studies, therefore, remains elusive, especially when one bears in mind that blood 
pressure lowering can also be obtained by medication alone." Reporting all actual data 
on blood pressure, as well as the amount and type of antihypertensive drugs used, may 
provide a more accurate comparison between results of the various studies. The best way 
to express the amount of antihypertensive drugs is, to our knowledge, the calculation of 
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Defined Daily Doses (DDDs) according to the World Health Organization to reflect both 
the number and dosage of the prescribed drugs." In concurrence with results after PTRA, 
a beneficial effect of renal artery stent placement on renal function has not been 
convincingly established. Nevertheless, 30% of the patients with renal failure was 
regarded as improved and 38% as stabilized, which may indicate that the effect of stent 
placement on renal function may be stabilization rather than statistically significant 
improvement. It is noteworthy that the most recent studies focused on the effect of 
renal artery stent placement on the management of renal function,15.11,18 while the 
effects on hypertension seem to be of less importance, This shift-of-focus from 
hypertension to renal function seems not be justified regarding the data on blood 
pressure and renal function among the studies reviewed, It should be noted, however, 
that hypertension has been the subject of numerous previous studies, and renal function 
has been somewhat ignored, which may be corrected in the later studies, 
The averaged restenosis rate following renal artery stenting of 17% (range 0% to 39%) 
after six to 29 months follow-up concurred with restenosis rates in coronary arteries. J5 
Restenosis rates were significantly lower than after PTRA alone, although again a 
randomized trial would be warranted to investigate this topic in more detail. The cause 
of the different restenosis rates between the different studies was not clearly 
established, nor were the mechanisms related to restenosis. 
Calculation of correlations between the different variables revealed that older patients 
had less benefit from stent placement with regard to hypertension than younger 
patients, This may reflect the coexistence of essential hypertension and irreversible 
arteriolosclerosis in older patients. A serious limitation associated with the calculation of 
correlations between the different variables across the studies is the absence of raw data, 
The fact that, for example, one patient may have undergone two stent placement 
procedures could not be taken into account in an analysis as presented in this study. 
Therefore, conclusions must be interpreted carefully, For the same reason, we were 
unable to perform a multivariate regression analysis, which may establish the prediction 
of outcome of intervention based on patient or lesion characteristics. The results of our 
study, however, demonstrate that such an analysis would be interesting to perform, 
Comparison between stent placement and PTRA showed higher initial success rates and 
lower restenosis rates after stent placement. The percentage of patients cured from 
hypertension tended to be higher after stent placement than after PTRA, The results as 
presented here were in accordance with the results of the randomized trial comparing 
renal artery stent placement with PTRA." In the latter study renal artery stent 
placement was a better technique than PTRA to achieve vessel patency with higher 
technical success and lower restenosis rates (88% vs 57% and 14% vs 48%, 
respectively)," The clinical outcome, however, was not significantly different between 
stent and PTRA, In the meta-analysis presented here, stent placement was associated 
with a lower percentage of patients with improved renal function, This may be due to 
the fact that the stent studies included more patients with impaired renal function 
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instead of hypertension, which may affect the clinical outcome in terms of renal function. 
It should be stressed that the major limitation of the present study is that it is not a 
randomized controlled clinical trial. Although randomized controlled clinical trials are 
the superior mode for evaluating and comparing therapeutic interventions, they also 
have limitations." First, a randomized trial. performed in an ideal setting with a 
selected, usually small, patient population may hamper generalization of the results. 
Second, these trials are costly and often have a short follow-up period for both practical 
and ethical reasons. Meta-analysis of cohort studies, on the other hand, may reflect the 
general clinical practice, is cheaper and supplies additional data on a larger number of 
patients and may be a reasonable alternative for a randomized controlled clinical trial. 
However, it should be acknowledged that a meta-analysis as presented here has 
well-known deficits including unequal number of patients and different end-points 
between the studies. A multi-center trial with uniform patient entry criteria and 
outcome measures would provide valuable results. 
NEED FOR FUTURE STUDIES 
The following issues need to be addressed in future studies: 
• The assessment of the outcome of PTRA, stent placement and optimal 
medical therapy in a randomized controlled setting. 
II The long-term effects of the treatment modalities on blood pressure, 
renal function and restenosis rates. Accurate monitoring of the 
amount of antihypertensive medication in Defined Daily Doses is of 
critical importance, since inaccuracies blur the outcome of 
intervention. 
• Optimal visualization of the effect of end avascular renovascular 
intervention. Possible modalities are the use of intravascular 
ultrasound" and magnetic resonance angiography. J8 
CONCLUSIONS 
Renal artery stent placement appears to be superior, regarding initial success and 
restenosis rates and clinically comparable to PTRA alone. Future studies are needed to 
focus on the prevention of complications and on the assessment of long-term benefit, as 
well as on the factors determining success or clinical failure of the intervention. 
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To investigate the feasibility of 
using intravascular ultrasound 
to characterize nonnal and 
diseased renal arteries, renal 
artery specimens removed at 
autopsy were studied in vitro. 
Intravascular ultrasound 
images were qualitatively and 
quantitatively analyzed and 
compared to the histologic 
findings as gold standard. 
This study showed intravascular 
ultrasound to be a reliable 
technique for distinguishing 
renal arteries with or without a 
lesion. Also, it appeared that 
both plaque development and 
local vessel narrowing may 
result in renal artery stenosis. 
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Renal artery stenosis may cause renovascular hypertension and may lead to renal 
dysfunction. '-3 Stenosing plaques are most common at the proximal part of the renal 
artery and are usually bilateral.'·s Atherosclerotic lesions account for 70-75% of the renal 
artery stenoses, the remainder being due to fibromuscular dysplasia. 6•7 
Percutaneous transluminal renal angioplasty (PTRA) has been advocated as the treatment 
of choice for renal artery stenosis. Long-term results of PTRA show that cure rates are 
mainly dependent on the type of lesion involved: cure rates for hypertension arising 
from fibromuscular dysplasia are better than for atherosclerotic renal artery stenosis.6•7 
Intravascular ultrasound (IVUS) is a unique way of obtaining cross-sectional morphologic 
and quantitative data of the normal and diseased arterial wall in vivo.'" Previous studies 
in coronary arteries have established that adaptive remodeling of the vessel can 
compensate for the accumulation of atherosclerotic plaque.tO.l! Furthermore, arterial 
shrinkage is now recognized as an important factor in peripheral arterial stenosis." 
In the present in vitro study, we compared qualitative IVUS findings in renal arteries 
with histology as gold standard, and determined the quantitative characteristics of renal 
artery stenosis. 
METHODS 
Human specimens 
Renal arteries attached to the abdominal aorta (n=44) were removed from 21 consecutive 
humans over 40 years of age (14 males, seven females; median age 66 years, range 42-88) 
at autopsy. Twelve of these patients had coronary artery disease, three had peripheral 
vascular disease, five had cerebrovascular disease, nine had hypertension, and three had 
end-stage renal failure. The specimens were stored frozen at -20°C. For the in vitro study, 
the specimens were thawed, and side-branches and the proximal and distal ends of the 
aorta were tied off with sutures. The distal ends of the renal arteries were connected 
with sheaths and fixed in a waterbath at room temperature (Fig. 1). During the study, 
the arteries were pressurized at 100 mmHg by means of a fluid reservoir containing water 
connected to the side arm of the sheath. 
Intravascular ultrasound 
A mechanical 30 MHz imaging system, designed for clinical use, was used with a Princeps 
30 MHz 4.3F catheter (Endosonics, Rijswijk, The Netherlands). Since access to the renal 
artery from the aorta was impossible due to the acute angle of the renal artery, the IVUS 
catheter was introduced via the sheath distal in the renal artery and advanced up to the 
aorta. A displacement sensing device was used to match IVUS images with the 
corresponding histologic sections." Displacement of the ultrasound catheter tip in steps 
of 0.1 mm was related to a reference site (the aorta) and mixed automatically with the 
ultrasound information on a videoscreen. IVUS images were made during pullback of the 
catheter and stored on S-VHS videotape for further analysis. 
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Figure 1. In vitro set-up showing the intravascular ultrasound catheter advanced through the sensing 
unit of the displacement sensing device and sheath distal into the pressurized renal artery. 
Histology 
For histologic comparison, the arteries were fixed under pressure (100 mmHg) in 10% 
buffered formalin for 2 hours, and subsequently decalcified in a standard rapid 
decalcification solution (Apex Ine., Plainfield, Illinois, USA) for 5 hours. The arteries 
were processed for routine paraffin embedding. Transverse sections (5 JIm thick) were cut 
perpendicular to the long axis of the vessel at 10 mm intervals. Pathologic sections of 
the artery, marked with a needle, were cut at 1 mm intervals, and stained with elastic 
van Gieson and hematoxylin· eosin techniques. 
Qualitative analysis 
Data from the displacement sensing device and from the aorta as an anatomical marker 
were used to correlate IVUS images with the corresponding histologic sections. To assess 
lesion morphology, two to four sets of corresponding IVUS images and histologic sections 
were selected from each vascular specimen, including the most stenotic site. The renal 
arterial wall was defined as normal when wall thickness (Le. intima and media) was 0.5 
mm or less. A distinction was made on IVUS between bright lesions superimposed on the 
arterial wall with or without peripheral shadowing. Lesion morphology identified on 
histologic sections included fibromuscular lesions with or without calcifications. A 
fibromuscular lesion was defined as a lesion mainly composed of smooth muscle cells and 
a disorderly arrangement of elastin fibers. Calcification was defined as calcium crystals 
within a fibromuscular lesion seen on the sections stained with the hematoxilin·eosin 
technique. Lesions were classified on IVUS as eccentric and concentric. A concentric 
lesion was involved when the whole vessel was diseased and an eccentric lesion was 
present when a part of the vessel wall was disease· free. The location of the most stenotic 
site (Le. smallest lumen area) recorded by IVUS was defined as ostial (Le. within 10 mm 
from the aorta), or as truncal (Le. non-ostial)." 
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Quantitative analysis 
A multitude of IVUS cross-sections was quantitatively analyzed with an interval of 5 mm. 
Analysis included assessment of lumen area, vessel area, plaque area, and percentage 
area obstruction (Table 1). Lumen area was defined as the area encompassed by the inner 
boundary of the intimal surface. Vessel area was defined as the native vessel area 
bounded by the medial-adventitial border. Plaque area was obtained by subtraction of 
lumen area from vessel area. Percentage area obstruction was calculated as plaque area 
divided by vessel area. From each vascular specimen a target site and a reference site 
were selected. The target site was the IVUS cross-section with the smallest lumen area. 
The reference site was the IVUS cross-section with the largest lumen area (before the 
first major side-branch) proximal or distal to the target site. The vessel area measured at 
the target site was expressed as a percentage of the vessel area measured at the 
reference site by dividing the target site vessel area by the reference site vessel area, and 
multiplying by 100. A relative vessel area of >110% at the target site represented a larger 
vessel area (group I), 90-110% indicated no change (group II), and a vessel area of <90% 
indicated a smaller vessel area at the target site with respect to the reference site (group 
Ill). A cut-off point of 10% was used to correct for interobserver differences in 
measurements. 
To determine whether vascular tapering was present,!S a second reference site was chosen 
from each vascular specimen 10 mm distal to the target site and analyzed for vessel area. 
A comparison was made between the mean vessel area obtained at the target site, the 
reference site 10 mm distal to the target site, and the reference site before the first 
major side-branch distal to the target site. 
The relationship between the extent of lesion, the relative vessel area, the location of 
the target site (ostial or truncal), and the reference site (proximal or distal to the target 
site) on the one hand, and patient's age and sex on the other hand, was determined. 
The reproducibility of IVUS parameters used in this study has been reported previously.!6 
For the present study, quantitative analysis of both lumen and vessel area of 40 
preselected IVUS cross-sections was repeated after three months in order to determine 
the intraobserver variability in measurements. 
Statistical analysis 
Data are expressed as means ± SD. Measurements of the target and reference site and 
intraobserver differences were analyzed with Student's t-test for paired observations. The 
degree of intraobserver variation was presented as a coefficient of variation, defined as 
the SD of the paired differences divided by the mean of the absolute values. p<0.05 was 
considered statistically significant. 
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RESULTS 
In 41 of the 44 renal artery specimens lVUS investigation was completed successfully. In 
three specimens, the lVUS catheter was advanced subintimally; these specimens were not 
used for further analysis. The mean length of the renal arteries studied up to the first 
major side· branch was 32 mm (range 12 to 65 mm). As the catheter was pulled back, it 
became evident that lumen area changed markedly. 
Qualitative analysis 
From the 41 renal artery specimens, 130 corresponding lVUS images and histologic 
sections were available for analysis. The renal arterial wall was characterized on lVUS by 
a three-layered structure specific for muscular arteries: a hypoechoic media with clear 
definition of the intima and adventitia, showing bright echoes (Fig. 2). In 55 lVUS 
cross-sections, there was no evidence of a lesion; this was in agreement with the 
histologic results. Bright lesions seen on lVUS (n-75) corresponded with fibromuscular 
lesions on the histologic sections. In 31 of the 75 cross-sections, part of the lesion 
showed peripheral shadowing corresponding with calcium deposits seen histologically. 
Calcifications observed by lVUS were scored false positive on five cross-sections and false 
negative on four cross-sections. The sensitivity of lVUS in detecting calcifications was 
87% and the specificity was 89%. Of the 75 lesions, 17 were concentric and 58 were 
eccentric on lVUS imaging. The most stenotic site was located near the ostium in 20 
specimens (ostial lesion) and in the truncus in 21 specimens (truncal lesion). 
Quantitative analysis 
All 20 ostial lesions had a distal reference site. Of the 21 truncal lesions, 13 had a 
proximal reference site and eight had a distal reference site. Quantitative data on the 
target and reference site are given in Table 1. 
Table 1. Quantitative data of 41 renal arteries studied with intravascular ultrasound in vitro 
Group I (n = 8) Group II (n = 12) Group III (n .. 21) 
Target Reference Target Reference Target Reference 
Lumen area (mm2) 16.9 ± 7.8' 25.0 ± 9.5 15.1 ± 8.1' 20.7 ± 9.8 15.5 ± 8.9& 23.1 ± 10.5 
Vessel area (mml) 43.1 ± 10.7! 33.9 ± 10.1 30.2 ± 14.3 30.6 ± 14.0 25.3 ± 12.4' 33.3 ± 14.6 
Plaque area (mml) 26.2 ± 5.6& 8.9 ± 1.6 15.1 ± 8.1' 9.9 ± 5.6 9,8 ± 5.2 10.2 ± 5.4 
Area obstructed ("10) 62.4 ± 12.0& 28.0 ± g.O 49.5 ± 14.7& 32.2 ± 11.0 40.3 ± 16.0· 30.4 ± 8.3 
Values are means ± SD. Specimens were grouped on the basis of whether the target site had a larger (>1100/0; group I), 
similar (90·110%; group II) or smaller vessel area «90%; group Ill) than that of the reference site . 
• p <0.05, 'p <0.01, &p <0.001, versus reference site. 
49 
Chapter 4 
In group I (n=8 of which six were ostial) the lumen area decrease was mainly due to the 
extent of plaque, and was associated with a large vessel area (Fig. 3). In group II (n=12 
of which five were ostial) decrease in lumen area at the target site was solely caused by 
the extent of plaque. In group III (n=21 of which nine were ostial) decrease in lumen 
area at the target site was associated with a significantly smaller vessel area than at the 
reference site (p<O.OOl); the plaque area was as small as that at the reference site. A 
diagrammatic representation of the three groups is shown in Figure 4. Data on the 
reference sites showed little variation in vessel area between the groups (30.6±14.0 mm' 
to 33.9±10.1 mm'). 
.-
Figure 2, Intravascular ultrasound cross-sections 
and their histologic counterpart (elastic van 
Gieson staining). The inner contour presents the 
lumen area and the outer contour the vessel area. 
The upper panel shows a normal renal artery with 
a three-layered structure. The middle panel 
shows a renal artery with a fibrous lesion (from 
11 to 4 o'clock). No calcifications are evident. 
The lower panel shows a fibrous lesion in the 
renal artery (from 6 to 12 o'clock) with 
calcification (arrow). Note the absence of echo 
reflections behind the calcification. 
Calibration.,. 1 mm; + represents the catheter. 
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Figure 3. Intravascular ultrasound cross-sections 
obtained from renal arteries showing the target 
site (left panel) and the reference site (right 
panel). The inner contour presents the lumen 
area and the outer contour the vessel area. 
The vessel area at the target site is larger (upper 
panel), in the same order (middle panel), and 
smaller (lower panel) than at the reference site. 
Calibration = 1 mm; + represents the catheter. 
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Comparison between the mean vessel area at 
~~~~~~ the target site (30.2±14.1 mm'), the reference 
site 10 mm distal to the target site (31.7±13.8 
mm'), and the reference site before the first 
major side-branch distal to the target site 
---------
-------------~4V?:::~0::S,'=;;;;:_'%;:~::q;::y':91 
(mean 15 mm; 33.B±14.0 mm') revealed no 
tapering of the renal artery. 
In 15 of the 41 specimens studied, no lesion 
was scored with qualitative analysis at the 
target site. This was in agreement with the 
histologic results. Five of these normal target 
sites belonged to group II and 10 to group III. 
The relative vessel area for ostial lesions was ~~_~AC#"W$~~~* •••. ~ ••..• nN":'4 significantly larger than for truncal lesions 
= = = = = = = = = = = = = (99.3±24.5 vs. 85.2±19.6, respectively; 
J&!1tF*,p+,/g!£!k!hG;'J.(<!():Wf!J&}!')Y"':!M'it%0i0tS.1'i:40i'\)4(N{¢;X'P:J8PM ;'3 p=D.05). For ostial lesions significant larger 
Figure 4. Diagram of three types of renal artery 
stenosis. In group I, renal artery stenosis was the 
result of an increase of both vessel and plaque 
area; in group II, plaque area was the only 
contributor to renal artery stenosis; and ill group 
III, the renal artery stenosis was caused by a 
decrease in vessel area with respect to the 
reference site; the plaque area did not increase. 
plaque areas were found than for truncal 
lesions (19.1±9.0 mm' vs. 9.7±5.2 mm', 
respectively; p<0.001). The relative vessel area 
calculated for vessels with a proximal 
reference site was significantly smaller than 
for vessels with a distal reference site 
(7B.B±14.7 vs. 9B.7±23.B, respectively; 
p=O.OOB). In a review of the histologic 
sections for potential differences in the media, external elastic lamina and adventitia 
between the target and the reference sites and between the three groups, the only 
difference found was a marked thickening of the external elastic lamina at the target site 
of group I compared with a thin, well-defined external elastic lamina seen at the 
reference site. 
No relationship was evident between patient's age, the quantitative IVUS measurements 
and location of the lesion. Measurements of lumen, vessel. and plaque gave significantly 
higher values in males than in females. Relative measurements (target values divided by 
reference values), however, were not significantly different. Intraobserver differences for 
lumen and vessel area were not significant (p=0.193 and p=0.112, respectively) with a 
coefficient of variation of 3.4% for the lumen area and 11.4% for the vessel area. 
DISCUSSION 
With the development of new techniques for the. endovascular treatment of renal artery 
stenosis, there is an increasing need for optimal knowledge and visualization of renal 
artery pathology. In the present study renal artery pathology revealed by IVUS imaging 
was compared with histology findings, used as gold standard. 
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Qualitative analysis 
Bright lesions on IVUS corresponded with fibromuscular lesions on histology. The 
sensitivity and specificity of IVUS in detecting calcifications were good (87% and 89%, 
respectively). These results concur with those of other studies reporting a sensitivity of 
77-97% and a specificity of 98-99%."'" In our study, four of the five false-positive and 
four false-negative calcifications scored on IVUS can be explained by the difficulty to 
detect shadow behind a lesion in the absence of surrounding tissue. This problem is 
inherent to in vitro studies and may not be encountered in clinical studies. In one 
false-positive scored calcification on IVUS a dense fibrotic cap imitated the ultrasound 
signal of a calcified lesion. In a previous IVUS study we documented that densely 
organized fibrous tissue may induce excessive attenuation of the ultrasound signal. 
suggesting calcification.20 
Quantitative analysis 
In the present study, we compared quantitative IVUS measurements from the target site 
with those obtained at the reference site. The lumen area at the target site was similar in 
all groups selected. Percentage area obstruction, however, differed between the groups 
and was strongly related to plaque load and vessel area. In 20% of the specimens (group 
I) a relatively large vessel area was seen at the target site, probably in response to plaque 
area increase, a process also described by Glagov et al. lO In 29% of the specimens (group 
II) lumen area reduction was solely caused by the extent of plaque. In 51% of the 
specimens (group Ill), however, lumen area reduction was associated with a small vessel 
area at the target site with respect to the reference site. The plaque burden seen at the 
target site was as low as at the reference site. Similar local differences in vessel size were 
described in coronary arteries and in peripheral arteries. 1,•11 Pasterkamp et al. 11 regarded 
the small relative vessel area at the target site as either shrinkage or as failure to 
enlarge. In the present study small relative vessel areas were encountered without 
histologic abnormalities; the potential mechanisms related to this phenomenon remain 
unknown. In 1994 Gibbons and Dzau" reported on the alteration of vessel structure 
(remodeling) in response to increased arterial pressure. Active restructuring of the 
cellular and noncellular components of the vessel wall resulted in marked changes in 
luminal dimensions, with relatively small changes in wall thickness. Whether this process 
may explain the findings of the present study needs to be established in future studies. 
In order to acquire insight in the cellular mechanisms that may explain the findings of 
the present study, one could assess the expression of genes for vasoactive factors, such 
as platelet-derived growth factors and transforming growth factor-p1 at the target and 
the reference site. 
Comparison of mean vessel area measured at the target and distal reference sites showed 
that tapering did not occur in the selected renal arteries. It is noteworthy that these 
features can not be evidenced by angiography, a technique unable to provide 
cross-sectional imaging and wall morphology. 
In the present study, ostial lesions had significantly larger relative vessel areas and 
larger plaque areas than truncal lesions. This finding suggests that ostial lesions are 
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mainly caused by plaque development and truncal lesions mainly the result of a small 
vessel area. We found no significant differences in lesion locations between males and 
females. However, the significant differences in vessel dimensions between males and 
females have to be taken into consideration in clinical practice (e.g. for balloon size 
selection). 
From a clinical viewpoint. we postulate that absence of a large plaque burden and a small 
relative vessel area at the target site may have important implications for selecting the 
optimal treatment of renal artery stenosis. For example, PTRA and stent placement may 
have a different outcome in renal arteries obstructed by atherosclerotic plaque as 
opposed to constricted renal arteries. Clinical studies with IVUS are needed to establish 
whether this assumption is correct. 
Study limitations 
Some potential limitations of the present study need to be addressed. First, data derived 
from the specimens used in this study may represent an anatomic substrate different 
from that in clinical series of patients undergoing renal artery interventions. Second, 
comparison of a target and a reference site gives a problem concerning the definition of 
those sites. In the present study lumen area magnitude was considered to be most 
important in developing hemodynamically significant renal artery stenosis, and therefore 
target and reference sites were selected as those sites with the smallest and largest 
lumen area, respectively. Third, the reference site may undergo compensatory dilatation 
(post-stenotic dilatation) and falsely demonstrate a small vessel area at the target site. 
However, we believe that compensatory dilatation of the reference site was not an 
important factor in this study, because vessel area at the reference site did not differ 
markedly between the groups, and post· stenotic dilatation (by definition distal to the 
target site) did not occur in 13 proximal reference sites. Finally, it should be remembered 
that changes in arterial dimensions occur over time. By choosing target and reference 
site in the same artery, the assumption was made that different sites in one artery are 
representative for the narrowing process over time. Whether this assumption is correct 
needs to be established in serial studies. 
In conclusion, IVUS proved to be reliable in distinguishing renal arteries with or without 
a lesion. Apart from atherosclerotic lesions, local differences in renal arterial wall 
dimensions may be important in the development of renal artery stenosis. 
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A recent study of human 
cadaveric renal arteries 
revealed that renal artery 
narrowing could be due not 
only to atherosclerotic plaque 
compensated for by adaptive 
remodeling, but also to hitherto 
undescribed focal narrowing of 
an otheTvdse nonnal renal 
arterial wall (i.e. coarctation). 
The present study showed that 
vessel coarctation could also be 
identified in patients with 
symptomatic renal artery 
stenosis (RAS). 
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It is generally accepted that atherosclerotic plaque accumulation is the principal cause of 
renal artery stenosis (RAS)Y A recent intravascular ultrasound (IVUS) study in human 
renal arteries obtained at autopsy, however, suggested an alternative cause of RAS. 3 In 
that study we observed that in 60% of the specimens plaque accumulation with or 
without compensatory vessel enlargement (i.e. adaptive remodeling) caused lumen 
narrowing. This phenomenon was first described by Glagov et al. ' and, subsequently, by 
others. 5.6 In the remaining 40% of the specimens, however, focal narrowing of the renal 
artery wall with little or no plaque was observed. Here, we propose the term 
"coarctation" to describe the latter condition (Dorland's Medical Dictionary defines 
"coarctation" as "a condition of stricture or contraction tl 7). 
If this condition is present in vivo, it might cause hemodynamically significant RAS. 
However, to the best of our knowledge, renal artery coarctation has not been described 
before in vivo, especially not in patients with atherosclerotic renal vascular disease. The 
first aim of the present study was, therefore, to establish whether renal artery 
coarctation could be identified as a contributing factor to RAS in symptomatic patients 
with angiographically proven renal artery stenosis. The second aim was to identify 
angiographic and/or clinical variables that might be predictive for the distinguishing 
lesions. 
METHODS 
Between September 1996 and March 1999, we studied 48 consecutive patients (16 f, 32 
m, aged 59±9 years [mean±SDJ) with hypertension and/or renal function impairment and 
atherosclerotic RAS who were referred for percutaneous transluminal stent placement 
guided by IVUS. Previous angiograms had revealed >50% diameter stenosis in all patients. 
The Local Committee on Human Research approved the investigation. Patients were 
included in the study after informed consent was obtained. 
Revascularization was performed via the femoral approach. The stenosis was crossed with 
a 5F selective catheter in combination with a 0.035-in hydrophylic guidewire [Terumo, 
Tokyo, Japan]. The hydrophylic wire was exchanged for a 0.020-in stiff guidewire with a 
flexible tip [Boston Scientific, Blilach, Switzerland] for guiding the IVUS catheter, the 
angioplasty balloon and the balloon-expandable stent. A 3D-MHz mechanical IVUS 
imaging system was used with 4.3F catheters ("Princeps", Endosonics, Rijswijk, The 
Netherlands).' The IVUS catheter was positioned distally from the stenosis in the first 
major side-branch. Real time cross-sectional images of the renal artery wall obtained 
during slow pullback of the IVUS catheter were displayed on a monitor and stored on 
S-VHS videotape for off-line analysis. 
Image analysis 
From each renal artery, multiple IVUS cross-sections were quantitatively analyzed to 
select the target site and a reference site for further analysis. The target site was the 
IVUS cross-section with the smallest lumen area. The reference site was the most distal 
cross-section in the renal artery truncus with a normal appearance. 
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Analysis included assessment of lumen area (LA), media-bounded area (MBA), plaque 
area (PLA) and percentage area stenosis_ LA was defined as the area encompassed by the 
inner boundary of the intimal surface_ MBA was defined as the native vessel area 
bounded by the external elastic lamina. PLA was calculated by subtraction of LA from 
MBA. Percentage area stenosis was calculated as LA at the target site divided by the LA 
at the reference site. 
The MBA at the target site was expressed as a percentage of the MBA at the reference 
site. A relative MBA of >85% at the target site indicated a similar or larger MBA 
("adaptive remodeling" group) and a relative MBA of <85% at the target site indicated a 
smaller MBA than at the reference site ("coarctation" group). Based on our previous 
observation that tapering of the renal artery does not occur,' we used a 15%-tolerance 
interval to define a smaller MBA, to be on the conservative side. It was assessed whether 
the conclusions of the quantitative analysis, which were performed by two independent 
observers (TeL, JAvE), were consistent for the two observers individually. Mean values of 
the two observers are given. 
Statistical analysis 
The two groups were compared with regard to the MBA and PLA at the target and the 
reference sites, relative MBA and percentage area stenosis. Student's t-tests were used at 
the p < 0.05 significance level. 
Interobserver variability for quantitative IVUS measurements was quantified by 
regression analysis and a coefficient of variation, defined as the standard deviation of 
the paired difference divided by the mean of the absolute value. 
Multivariate logistic regression analysis was performed to predict the presence of either 
of the two lesions. A logistic regression model was fitted including angiographic and 
clinical parameters as the independent variables. Angiographically, a distinction was 
made between ostial and truncal lesions.' Dependence on the following clinical 
characteristics was assessed: age, sex, signs and symptoms of atherosclerotic vascular 
disease (angina pectoris, intermittent claudication, cerebrovascular accident or vascular 
surgery), duration of hypertension «1 year, 1-2, 2-5 or >5 years), smoking history (ever 
or never), obesity (body mass index >25 kg/m'), serum creatinine concentration and 
hypercholesterolemia (serum cholesterol level >6.5 mmol/L or use of cholesterol-lowering 
agents). In addition, we assessed whether any differences were found in the initial 
technical success rate and the three months clinical results (systolic and diastolic blood 
pressure, number of antihypertensive drugs and serum creatinine level) between the two 
groups. 
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RESULTS 
IVUS images were obtained in 18 patients before intervention and in 18 other patients 
after predilatation with an angioplasty balloon 5 or 6 mm in diameter. In the remaining 
12 patients, the interventionist did not use IVUS before stent placement. 
Quantitative IVUS data for the group studied before intervention are given in Table 1. 
Nine out of 18 patients showed the coarctation phenomenon with an MBA at the target 
site of 24.0±5.1 mm', which was significantly smaller than in the adaptive remodeling 
group (33.9±6.8 mm', p = 0.003; Figure). PLA in the coarctation group (13.9±4.4 mm') 
was also significantly smaller than in the "adaptive remodeling" group (23.7±6.1 mm'; 
p =0.001). Quantitative parameters at the reference site and the degree of area stenosis 
were not significantly different between the two groups. Similar results were 
encountered in the 18 patients studied after predilatation Table 1. 
The two observers showed good observer agreement with regard to the IVUS 
measurements, with high correlation coefficient (r=0.98; observer-2 = 0.98 * observer-l 
+ 0.64 mm'), and an overall coefficient of variation of 10.7%. The conclusions were 
consistent for each observer individually. Multivariate regression analysis did not reveal 
any angiographic or clinical parameter predictive for either adaptive remodeling or 
coarctation; no differences were encountered in initial technical success and 3-month 
clinical outcome between the two groups. 
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Figure 1. Intravascular ultrasound 
cross-sections obtained from renal 
arteries before intervention showing 
the adaptive remodeling (A) and the 
coarctation type of renal artery 
stenosis (B), 
The left panel represents the target 
site and the right panel the reference 
site. The cross-sections are contour-
traced, facilitating the recognition of 
lumen area (inner contour) and media-
bounded area (outer contour). 
Note the small relative media-bounded 
area and litHe plaque in the 
coarctation stenosis (B). 
Calibration = 1 mm; 
black circle = catheter. 
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Table 1. Quantitative cross-sectional intravascular ultrasound data of renal arteries before 
intervention (18 patients) and after predilatation (18 patients). 
Adaptive 
remodeling 
group 
Before intervention n~9 
Target 
MBA, mm l 33.9 ± 6.8 
PLA, mm2 23.7 ± 6.1 
Reference 
MBA, mm2 33.5 ± 7.6 
PLA, mm2 7.9 ± 2.0 
MBA target/reference, % 103 ± 13 
Area stenosis target/reference, °10 61.2 ± 19.7 
After predilatation n .. 10 
Target 
MBA, mm2 43.0 ± 12.4 
PLA, mm2 28.2 ± 13.0 
Reference 
MBA, mrn2 33.2 ± 6.3 
PLA, mm2 7.8 ± 1.9 
MBA target/reference, O/Q 130 ± 31 
Area stenosis target/reference, % 42.5 ± 18.0 
Coarctation 
group 
n-9 
24.0 ± 5.1 
13.9 ± 4.4 
33.9 ± 3.8 
7.8 ± 1.4 
71 ± 11 
61.4 ± 19.3 
n-8 
24.1 ± 10.6 
12.3 ± 8.0 
35.2 ± 17.1 
6.9 ± 2.8 
70 ± 10 
52.1 ± 17.3 
p 
0.003 
0.001 
NS 
NS 
< 0.001 
NS 
0.004 
0.008 
NS 
NS 
< 0.001 
NS 
Renal arteries are divided into the "adaptive remodeling" and "coarctation" groups according 
to the relative media-bounded area (MBA) at the target site >85% and :;;85%, respectively. 
Values are mean ± standard deviation and represent the averaged results of the two 
independent observers. PLA= Plaque area, NS= Not significant. 
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DISCUSSION 
The conventional concept of development and progression of atherosclerotic RAS is the 
accumulation of plaque with or without compensatory vessel enlargement (i.e., adaptive 
remodeling). The current findings suggest an alternative substrate of symptomatic RAS, 
characterized by focal narrowing of the renal artery wall and little plaque (i.e., 
coarctation). The latter phenomenon was responsible for symptomatic RAS in 50% of 
patients, a prevalence of coarctation similar to that previously seen in our autopsy 
study. ) Coarctation could be identified even after balloon dilatation in 44% of the 
patients. The present study is the first in which coarctation as cause of RAS was 
evidenced clinically. It is noteworthy that 32 years ago, McCormack et al. 10 described a 
proportion of histologic RAS with "arterial spasm fixed by accumulation of collagen", 
which may reflect the coarctation as seen in the present study. In our previous autopsy 
study in which we combined IVUS with histologic analysis, however, coarctation was not 
associated with specific histologic characteristics. Mintz et al." described de novo 
stenotic lesions in coronary arteries that were characterized by inadequate remodeling 
and less plaque than expected. One might postulate that these coronary lesions are 
similar to the coarctation lesions in renal arteries seen in the present study. 
The pathogenesis of coarctation RAS obviously remains speculative at this stage. 
Abdominal aortic coarctation with or without involvement of the renal arteries may be 
related to renal artery coarctation, but as with fibromuscular dysplasia, Takayasu's 
arteritis and neurofibromatosis, this is a relatively rare cause of RAS that commonly 
involves younger patients. In the present study angiographic and clinical data were 
similar for both the adaptive remodeling and the coarctation groups. In the coronary 
artery study of Mintz et at" a significant association was found between inadequate 
remodeling lesions and the extent of lesion calcium. This led the authors to postulate 
that inadequate remodeling was a manifestation of advanced atherosclerosis. In the 
present study in renal arteries, however, only small, incidental speckles of calcium were 
present, both in the adaptive remodeling and in the coarctation groups. This, together 
with the fact that coarctation was also evidenced in human cadaveric renal arteries 
without plaque accumulation, suggests that in renal arteries, coarctation is a non-plaque 
determined phenomenon, possibly related to an early rather than a late stage of 
atherosclerosis, or perhaps not even related to atherosclerosis at all. 
Clinical implications 
The heterogeneity of atherosclerotic RAS as shown in the present study may have 
important clinical implications. Plaque-focused treatment by means of intravascular 
radiation therapy or plaque-lowering agents could be of minor importance for coarctation 
RAS. In addition, renal artery revascularization by either balloon angioplasty or stent 
placement is clinically successful in only part of the patient population treated .• 2 
Currently, which parameters determine the outcome of revascularization is insufficiently 
known. Whether the type of RAS determines the outcome of intervention is a question 
that will be investigated in future studies. 
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A limitation of our study was that IVUS images were not obtained in all 48 patients. This 
may have resulted in a selection bias; the prevalence of coarctation RAS as presented 
here must, therefore, be interpreted with caution. 
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patients. 
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Renal artery stenosis may cause renovascular hypertension and is an important cause of 
renal failure.!-' Results of percutaneous transluminal renal angioplasty are more 
encouraging for stenosis due to fibromuscular dysplasia than for atherosclerotic renal 
artery disease. ',5 Stenting of the renal artery may improve the treatment of 
atherosclerotic renal artery stenosis.6-8 Adequate stent expansion, however, seems to be 
an important factor determining success or failure of balloon-expandable stent 
placement.' 
It has been shown that intravascular ultrasound (IVUS) can provide accurate data on 
vessel dimensions, extent of the lesion involved, and the presence of stent 
underexpansion in patients undergoing renal artery interventions. lO•ll The present 
observational study was performed: 
1. to evaluate the contribution of IVUS-derived parameters to the 
procedure, 
2, to assess the qualitative and quantitative IVUS data obtained after renal 
artery stent placement, and 
3. to determine the short-term clinical outcome. 
MATERIALS AND METHODS 
Study group 
Between September 1996 and December 1997, 22 consecutive patients with symptomatic 
occlusive disease of the renal artery were referred for primary renal artery stent 
placement. The study group consisted 16 males and six females with a mean age of 60±10 
years. Patients were referred for drug-resistant hypertension (n=9), renal function 
impairment (n=10), or hypertension associated with renal failure (n=3). In all patients 
renal digital subtraction angiography revealed a stenosis >50%. Blood pressure was 
measured with a sphygmomanometer at three consecutive visits at least one to two 
weeks apart, three times per visit after five minutes of rest, with the patient in the 
upright position. Hypertension was defined as a diastolic blood pressure >95 mmHg. 
Patients were regarded as having drug-resistant hypertension if they remained 
hypertensive on a two-drug regimen. Renal function impairment was defined as a 
creatinine level >110 pmol/I (normal value range 50-110 pmol/I). The baseline 
characteristics of the patients are given in Table 1. The Local Committee on Human 
Research approved the investigation; patients were included in the study after giving 
written informed consent. 
Procedure 
Spiral CT of the upper abdomen was performed one or more days before renal artery stent 
placement in 14 out of 22 patients in order to determine the exact angle between the 
renal artery and the aorta for optimal stent placement.!' Procedures were performed by 
the femoral approach with a 9F introducer system [Cordis Europe, Roden, The 
Netherlands). In order to evaluate the technical results of the procedure, a 5F straight 
flush catheter was introduced through the contralateral femoral artery and placed just 
proximal to the renal arteries. A 5F catheter was advanced up to the renal artery ostium 
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and the stenosis was crossed with a O.035·in Terumo flexible wire. When the catheter 
had passed the stenosis the Terumo flexible wire was exchanged for a O.020-in stiff 
guidewire [Schneider Europe, Blilach, Switzerland]. Digital subtraction angiography was 
performed followed by pre dilatation of the stenosis. The balloon size selected was based 
on visual assessment of the angiographic reference lumen diameter proximal or distal in 
the renal artery (without interposition of side·branches). 
Table 1. Characteristics of the study population undergoing renal artery 
stent placement monitored by intravascular ultrasound. 
Patient characteristics Value 
Sex (male/female) 16(6 
Age (years) 61.3 ± 10.2 
Blood pressure (mm Hg) 
Systolic 178 ± 28 
Diastolic 96 ± 15 
Mean 123 ± 18 
Serum creatinine (pmal/l) 121 (71·427) 
Antihypertensive drugs (DDDs) 3.06 ± 1.49 
Coexisting risk factors 
Smoking 12 
Diabetes mellitus type II 1 
Coronary artery disease 12 
Peripheral vascular disease 9 
Cerebrovascular disease 4 
Values are expressed as mean ± standard deviation, except for serum 
creatinine which is expressed as median (range); 
ODDs. defined daily doses. 
Palmaz stents [Johnson & Johnson Interventional Systems, New York, USA] were used. 
Stent length was based on angiography and was the shortest possible that minimally 
overlapped the stenotic site with one mm. A slight protrusion of the stent into the aortic 
lumen was applied. The stents were mounted on a 5F balloon catheter and preloaded in a 
"hockey stick" BF guiding catheter [Cordis Europe, Roden, The Netherlands]. The guiding 
catheter-balloon-stent assembly was then passed over the guidewire across the lesion. 
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A V-connector [Namic, Tullamore, Ireland] attached to the guiding catheter was used to 
enable accurate control of stent positioning. The delivery system was then withdrawn 
into the aorta, leaving balloon and stent in situ. The balloon was inflated to pressures of 
10-12 Atm for 30 seconds. After removal of the balloon an angiogram was performed. The 
post-stent angiogram was considered successful based on a complete stent-vessel wall 
apposition and lesion covering and a residual diameter stenosis <10%. 
Just before stent placement the patients received an intra-arterial bolus of heparin 
(5,000 IU). For anticoagulation, after the procedure 20,000 to 30,000 IU heparin per day 
was given intravenously for 48 hours under control of the activated partial 
thromboplastin time, followed by oral acetylsalicylic acid (100 mg daily) for six months. 
Intravascular ultrasound 
IVUS studies were performed after predilatation and after angiographic successful stent 
placement (vide supra). A commercially available mechanical system containing a single 
rotating ultrasound element [30 MHz; Endosonics, Rijswijk, The Netherlands] was used 
with a guidewire tipped 4.3F flexible catheter ("Princeps"; 0.035-in). The system is based 
on a mechanically motor-driven rotating catheter tip element connected to a flexible 
drive shaft. The element is covered by an acoustically transparent dome. Axial resolution 
is 75 pm and lateral resolution is better than 225 pm at a depth of one mm. The unit is 
connected to a prototype instrument that provides continuous real-time cross-sections of 
the vessel wall (up to 16 images per second)." The ultrasound catheter was introduced 
over the guidewire through the guiding catheter and advanced distally beyond the renal 
artery lesion. Under fluoroscopic control, IVUS cross-sections of the diseased segment 
were obtained during slow pullback of the catheter. The resulting images, together with 
the fluoroscopic data, were displayed on a videoscreen and stored on S-VHS videotape. 
Qualitative analysis 
The angiographic levels and the corresponding IVUS cross-sections were analyzed for the 
presence of vascular damage after predilatation and after stent placement. 
Angiographically, vascular damage included dissection, defined as the presence of 
irregular contrast filling of the treated part of the renal artery. On IVUS vascular damage 
included dissection, plaque rupture, and vessel rupture". Dissection was defined as a tear 
in the intimal surface separating the lesion from the underlying arterial wall; plaque 
rupture was defined as a radial tear in the intimal surface perpendicular to the arterial 
wall, and vessel rupture was defined as an interruption in the internal elastic lamina and 
media that exposed the hyperechoic adventitia to the lumen. 
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Quantitative analysis 
First, during the procedure semiquantitative analysis of the IVUS images was applied in 
order to test whether the planned intervention required modification based on IVUS 
criteria. After pre dilatation, IVUS was used to assess whether the balloon size selected 
angiographically was correct. When the balloon diameter was more than 20% smaller 
than the reference lumen diameter, a larger balloon was selected for stent placement. 
After stent placement the success of the intervention on IVUS imaging was based on: 
" Complete stent-vessel wall apposition (absence of flow behind the 
stent struts). When incomplete apposition was present additional 
dilatation with or without a larger balloon was performed. 
" An intra-stent lumen diameter of at least 80% compared to the 
lumen diameter of the normal reference site; when the intra-stent 
diameter was more than 20% smaller than the reference lumen 
diameter, an additional dilatation with a larger balloon was 
performed. 
• The absence of a residual lesion proximal or distal to the stent; 
when a more than 20% lumen reduction compared to the smallest 
intra-stent lumen diameter was encountered, an additional 
dilatation or additional stent placement was performed. 
Second, to determine the ultimate effect of the intervention the IVUS images were 
quantitatively analyzed off-line, using a digital video analyzer system [International 
Business Machines, Boca Raton, FL].IS Analysis included assessment of the smallest 
intra-stent lumen area (i.e. target site), reference lumen area, balloon area, and 
percentage residual area stenosis after pre dilatation, after stent placement and (when 
performed) after additional intervention. Lumen area was defined as the area 
encompassed by the inner boundary of the intimal surface or by the stent circumference. 
Percentage residual area stenosis was defined as the difference between the lumen area 
at the reference site and the lumen area at the target site divided by the reference 
lumen area. 
In addition, a comparison was made between the smallest intra-stent lumen area and the 
lumen area measured at both stent edges. The difference between the lumen area at both 
stent edges and the smallest intra-stent lumen area was calculated and expressed as a 
percentage of the smallest intra-stent lumen area. A relative difference >10% indicated a 
larger stent edge. A cut-off point of 10% was used to correct for intra-observer 
differences in measurements. 
Fol/ow-up 
Patients returned for regular follow-up at the outpatient clinic. Blood pressure, the 
amount of antihypertensive drugs prescribed, and serum creatinine concentrations were 
monitored before stent placement and during follow-up of three months. Blood pressure 
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data were compared to the blood pressure values during the last three months prior to 
intervention. 
The use of antihypertensive drugs was recorded during the last three months prior to 
intervention, and during three months of follow-up. The amount of antihypertensive 
drugs was expressed as the summarized defined daily doses of the individual drugs 
(DDDs; the DDD is the assumed average maintenance dose per day for a drug used based 
on its main indication in adults).!6 
The median of all serum creatinine values measured in the year prior to the intervention 
was compared with the serum creatinine values at follow-up. In addition, using the 
Cockroft formula, glomerular filtration rates were calculated from each patient before 
intervention and at follow-up. 
Statistical analysis 
Quantitative measurements obtained after predilatation and after stent placement, and 
measurements of blood pressure, amount of antihypertensive drugs, serum creatinine, 
and glomerular filtration rates were compared using Student's paired t-test. Serum 
creatinine values were transposed in logarithmic values when performing a Student's 
paired t-test. A p-value <0.05 was considered statistically significant. Values are 
expressed as mean and standard deviation. 
RESULTS 
In two patients (9%) it was technically impossible to pass the stenosis with a guidewire 
because of severe calcification of the aorta and the lesion involved and to perform an 
intervention. Balloon size used for pre dilatation ranged from four to six mm. In 19 
patients a single stent was placed, and in one patient two stents were implanted. In 
total 10 p154 stents and 11 p204 stents were used. IVUS images were obtained in 18 of 
the 20 patients who received a stent; in one patient failure of the IVUS system was 
encountered and in another patient the ultrasound catheter could not be advanced into 
the renal artery following stent placement. No adverse effects attributable to the use of 
IVUS were observed. The total time required for the use of IVUS was five to 10 minutes. 
After predilatation IVUS images were obtained in nine patients; in five patients it was 
impossible to advance the ultrasound catheter over the guidewire into the renal artery 
and in four other patients the radiologist refrained to use the ultrasound catheter due to 
the potential risk for vessel damage. After stent placement IVUS images were obtained in 
all 18 patients. 
Qualitative analysis 
In six of nine patients studied with IVUS after predilatation, both angiography and IVUS 
revealed vascular damage. On IVUS a dissection was seen in four patients, a plaque 
rupture in one patient, and a vessel rupture in the remaining patient. Following stent 
placement, vascular damage seen on IVUS in five patients (dissection in four patients; 
vessel rupture in one patient; Fig. 1) was seen on the angiogram in two patients. 
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Figure la. After stent placement (5 mm baUoon) 
Figure lb. After additional dilatation (5 mm baUoon) 
Quantitative analysis 
Figure 1. Angiograms and 
corresponding intravascular 
ultrasound (NUS) cross·sections 
obtained after stent placement 
(A) and after additional 
dilatation (B), The contour in the 
NUS cross-section represents the 
lumen or stent area. IVUS images 
display (from right to left) the 
reference site, the distal stent 
edge, in-stent site, and the 
proximal stent edge in the aorta. 
After stent placement IVUS 
showed incomplete stent-vessel 
waH apposition (arrow), which 
was not seen on angiography. 
Note the discrepancy between the 
baUoon size (5 mm) and the 
smallest intra-stent diameter (3.6 
mm), and that the target site is 
located at the proximal stent 
edge. Additional dilatation 
performed because of incomplete 
stent·vessel wall apposition, 
resulted in an increase in lumen 
diameter and complete stent 
apposition. Note the small 
dissection (arrowhead) at the 
reference site, not evidenced 
angiographicaUy. + .. catheter; 
calibration to 1 mm. 
On the basis of semiquantitative analysis of the IVUS images after predilatation in five 
patients a difference more than 20% was encountered between the balloon diameter 
selected and the reference lumen diameter. In these patients it was decided to select a 
larger balloon for stent placement. 
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After stent placement: 
II Incomplete stent-vessel wall apposition evidenced in one patient was 
treated by additional dilatation (Fig. 1). 
II An intra-stent lumen diameter more than 20% smaller than the 
reference lumen diameter was observed in three patients and treated 
with additional dilatation using a larger balloon. 
" A lesion distal to the stent causing more than 20% obstruction was 
evidenced in two patients. Additional dilatation was performed in one 
patient, and additional stent placement in the remaining patient. 
On IVUS the final semiquantitative result after stent placement was successful in all 
patients. Table 2 summarizes the mean data obtained from the off-line quantitative 
analysis of the IVUS images. In the nine patients studied with IVUS after predilatation, 
stent placement resulted in a significant increase of lumen area (46%; p=O.OOl). The 
mean residual area stenosis decreased from 48% before stent placement to 32% after 
Table 2. Mean quantitative intravascular ultrasound data after predilatation, after stent placement and 
after additional intervention, and balloon size used. 
Target site Reference BaUoon % Area 
Study Group n (mm') site (mm2) (mm') Stenosis 
Patients studied after preditatation: 
After predilatation 9 13.lt 3.8 26.1 ± 7.5 22.7 ± 5.8 48 
After stent placement 9 19.1 ± 4.2 28.4 ± 6.0 27.3 ± 2.9 32 
Final result 9 21.6 ± 3.2 29.3 ± 5.3 28.4 ± 4.7 25 
Patients studied after stent placement: 
No additional intervention 12 22.3 ± 4.8 31.4 ± 9.8 28.6 ± 6.3 25 
Before additional intervention 6 18.2 ± 4.7 28.7 ± 10.8 26.8 ± 3.5 33 
After additional intervention 6 22.5 ± 5.9 32.2 ± 12.1 30.2 ± 7.2 28 
Final result 18 22.4 ± 5.0 31.7 ± 10.3 29.2 ± 6.5 26 
stent placement (p=0.097). In four of these patients an additional stent dilatation was 
performed. The final result of the nine patients showed a mean residual area stenosis of 
25%. Modification of the balloon size after pre dilatation based on IVUS imaging resulted 
in a good correlation between balloon size and reference segment (r=0.80; p=O.Ol). In 12 
patients with a successful semiquantitative IVUS result after stent placement, 
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quantitative analysis revealed a residual area stenosis of 25%. In six patients who 
underwent additional intervention based on IVUS after stent placement, lumen area 
increased significantly (24%; p=O.03) and residual area stenosis decreased from 33% to 
28%. Final results after stent placement of all patients showed a lumen area of 22.4±5.0 
mm' (mean lumen diameter 5.3 mm). The balloon size used for stent placement exceeded 
the resulting intra-stent lumen area (mean difference 22%; p=O.02). 
Comparing the smallest intra-stent lumen area and the lumen area measured at both 
stent edges individually it was found that in three stents the areas were in the same 
order. In three other stents the smallest intra-stent lumen area was smaller than the 
lumen area of both stent edges (range 15-51'10). In the remaining 12 stents either the 
lumen area at the proximal stent edge (i.e. in the aorta; n=4; range 23-48'10), or at the 
distal stent edge (n=8; range 11-37%) was larger than both the smallest intra-stent 
lumen area and opposite stent edge area. 
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Figure 2, Changes in systolic and diastolic blood 
pressure before and after stent placement. 
Figure 3. Amount of antihypertensive drugs 
prescribed before and after stent placement. 
Figure 4. Glomerular filtration rates before and 
after stent placement calculated from the 
Cockroft formula. 
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Follow-up 
All patients were followed for three months. One patient developed a rise in serum 
creatinine level after stent placement due to cholesterol crystal embolization, which 
appeared reversible at follow-up. Two patients known to have a serum creatinine >300 
pmol/l prior to intervention, became definitively dependent on hemodialysis after stent 
placement. The overall mean change in systolic and diastolic blood pressure is shown in 
Figure 2. The mean systolic blood pressure of 178±28 mm Hg before intervention showed 
a significant decrease to 150±26 mm Hg at one month (p<0.001) and remained 
significantly lowered at three months follow-up (162±33 mm Hg; p=O.Ol). Values for 
mean diastolic blood pressure before (96±15 mm Hg), at one month (85±14 mm Hg) and 
at three months follow-up (88±11 mm Hg) showed a similar significant decrease 
(p<0.001). The amount ODDs of antihypertensive drugs before and after stent placement 
is shown in Figure 3. Drug use decreased significantly from 3.06±1.46 ODDs before stent 
placement to 2.08±1.70 ODDs at one month, and to 1.99±1.23 ODDs at three months 
follow-up (p=0.002). 
Median serum creatinine level before stent placement (121 pmol/l; range 71-427) was 
stable at one month (121 pmol/l; range 52-364), but decreased to 96 pmol/l (range 
74-485) at three months follow-up. Student's t test on the logarithmic values of serum 
creatinine showed a p-value of 0.24. The effect of stent placement on renal function 
indicated by the mean glomerular filtration rate is shown in Figure 4. Filtration rates 
showed an increase from 62.10±28.52 ml/min before stent placement to 69.78±35.71 
ml/min at three months follow-up (p=0.09), suggesting some renal function 
improvement. 
DISCUSSION 
Combined balloon angioplasty and stent placement is rapidly gammg ground as the 
method of choice in the treatment of atherosclerotic renal artery stenosis. Stent 
placement is usually guided by angiography. The present study reports our first 
experience with renal artery stent placement guided by IVUS in a consecutive series of 22 
patients. 
In five patients IVUS imaging after predilatation was impossible due to the inferior slope 
of the renal artery, creating an acute angle with the aorta. In such cases it is likely that 
the left brachial approach described by Dorros et al.l7 gives more direct access into the 
renal artery; however, hemorrhagic complications with this approach are reported due to 
left brachial arterial puncture. t8 Whether this counterbalances better access into the 
renal artery needs to be established. In addition, the learning curve for the radiologist to 
use IVUS in renal arteries played an important role in their decision to use IVUS in the 
other four patients. Technical success rate for stent placement in the current study was 
91%. This was in accordance with the results of other studies on stent placement, '].I' but 
in contrast with the results following balloon angioplasty alone.'" 
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Qualitative analysis 
Comparison between angiography and IVUS after pre dilatation revealed no difference 
between the two modalities in detecting vascular damage. After stent placement, 
however, IVUS detected vascular damage in three patients that was not seen 
angiographically. A possible reason for this is that the presence of a stent in the renal 
artery may impair visualization of the adjacent reference segment angiographically. 
Vessel damage may also be missed on angiography when single-plane imaging is used. It 
is noteworthy that angiography was not able to distinguish between dissection, plaque 
rupture and vessel rupture; similar shortcomings were reported by Sheikh et al. lO 
Quantitative analysis 
In the present study, semiquantitative analysis of the IVUS images after predilatation 
showed that in five out of nine patients a larger balloon was selected to place the stent. 
Despite an angiographic successful result after stent placement, additional intervention 
was performed in six patients based on IVUS criteria. We assume that the incidence of 
incomplete stent-vessel wall apposition (one patient) and insufficient stent expansion 
(three patients) compared to the reference site seen on IVUS, may be reduced when the 
stent is placed with a high inflation pressure. This was previously described in stents 
placed in coronary arteries" and may also be applied in renal artery stent placement. In 
two of our patients IVUS revealed a lesion distal to the stent which implicates that the 
stent used was too short. Previous studies in coronary arteries showed that the plaque 
burden of the adjacent vessel segment was the predominant predictor of in-stent 
restenosis at the stent margins." We believe that in order to document the length of the 
lesion to be stented the use of a displacement sensing device may provide accurate 
information about the length of the lesion involved." 
Quantitative analysis of IVUS data in the present study showed that stent placement 
resulted in significant lumen gain compared with dilatation alone. Despite angiographic 
successful stent placement in six patients IVUS revealed a suboptimal result. Additional 
dilatation, with or without a larger balloon, or stent placement in these patients resulted 
in vascular damage, significant lumen gain and a reduction of residual area stenosis. Ellis 
et al." reported that the extent of residual stenosis after stent placement correlated 
highly with the incidence of restenosis in coronary arteries at follow-up. We postulate 
that IVUS may be beneficial in reducing restenosis rates by diminishing residual area 
stenosis. Future studies will show whether this hypothesis is correct. 
In the present study we learned that the lumen gain after additional intervention 
depended on the selection of a larger balloon for dilatation. Comparison between balloon 
size used and smallest intra-stent lumen area revealed a discrepancy of 22%. These 
findings concur with the data of Van Sambeek et al." in peripheral arteries, who 
observed a mean difference of 32-43% between balloon size and final intra-stent lumen 
area. It is noteworthy that in the present study the discrepancy of 22% remained after 
additional intervention. 
Comparing the smallest intra-stent lumen area and the stent area at both stent edges in 
all patients, IVUS evidenced that in only three stents the smallest intra-stent lumen area 
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was in the same order as the stent edge area. Surprisingly, in eight patients the proximal 
stent edge in the aorta was smaller than the distal stent edge. Compression of the stent 
by plaque" or plaque resistance" as a cause of inadequate stent expansion is unlikely in 
the present study, because these determinants are almost absent at the proximal stent 
edge in the aorta. A possible solution for this phenomenon is described by Henry et at. 27 
who tried to reshape the stent at the origin of the renal artery by dilating the proximal 
stent edge with a balloon larger than that used for initial stent placement. 
Analysis of the clinical benefits for our study group includes a significant decrease in 
systolic and diastolic blood pressure. After an initial fall, systolic and diastolic blood 
pressure values increased at one and three months follow-up. Blood pressure values in 
the present study are comparable with those reported by Taylor et at. 18 after stent 
placement in renal arteries. Other studies fail to report mean blood pressure values, or 
express results in terms of cure, improvement or worsening; however, the use of varying 
definitions for these parameters hampers adequate comparison of the results.'·18 A 
significant decrease in drug use was observed after the procedure. We expressed drug use 
as the number of DDDs to reflect both the number and the dosage of the prescribed 
drugs. Although the change in serum creatinine was not significant compared to the 
pre-stent values, median serum creatinine values decreased, suggesting improvement in 
renal function. Besides, glomerular filtration rates increased slightly at follow-up. In 
order to determine the effect of renal artery stent placement, Harden et at." analyzed 
the rate of progression of renal function impairment before and after stent placement to 
assess the effect of renal artery stent placement on renal function. Follow-up data of the 
present study are not sufficient to perform the same analysis, but a longer follow-up will 
determine the effects of renal artery stent placement on the preservation of renal 
function. 
Some potential study limitations need to be addressed. Only nine of the 18 patients were 
studied with IVUS after predilatation. Whether this problem can in part be solved by 
extra radiological appliances that give better access into the renal artery, or by the use 
of a different IVUS system, needs to be examined. Clinical follow-up at three months may 
be a too short period to allow valid conclusions about the effects of stent placement on 
the clinical parameters. We expect to solve these problems by a longer follow-up period 
of our patients in the near future. Finally, it should be acknowledged that considerable 
costs are associated with the use of IVUS; besides the ultrasound apparatus, IVUS 
catheters ($ 750) are needed. However, we believe that the use of IVUS for research 
purposes is definitely warranted to understand the parameters related to the short and 
long-term outcome of renal artery stenting. These results are not available yet. 
CONCLUSIONS 
IVUS monitoring of stent placement for the treatment of renal artery stenosis showed 
favorable technical and clinical results. Compared with standard angiography, IVUS 
provided additional information on lumen dimension and stent expansion, which 
influenced the intervention in several patients. 
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To allow determination oj the 
processes responsible for lumen 
loss at jollow-up in renal and 
jemoropopliteal Palmaz stents, 
the first consecutive patients 
treated with renal artery stents 
(n=4) andjemoropopliteal 
artery stents (n=3) jar 
occlusive vascular disease were 
studied with serial 
intravascular ultrasound. 
LUmen loss in renal artery 
stents appeared to be 
considerably less (17%) than in 
jemoropopliteal artery stents 
(62%). In the renal location, 
late lumen loss was due to 
neointimal tissue whereas stent 
area remained unchanged. Late 
lumen loss seen in 
jemoropopliteal artery stents 
was due to both neointimal 
tissue and stent area reduction. 
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In the ongoing evaluation of endovascular stents, serial intravascular ultrasound (IVUS) 
imaging has been used to assess vessel wall reaction and late lumen loss in different 
arterial segments.'" Apparently, the mechanisms for stent restenosis differ according to 
arterial location. In coronary stents, for example, IVUS imaging has shown that late 
lumen loss was mainly due to neointimal hyperplasia.'"' whereas neointimal hyperplasia 
and stent recoil have been reported in femoropopliteal stents.'-' Insofar as we know, 
IVUS has not been used to investigate late lumen loss in renal artery stents, so we began 
a study to preliminarily investigate the processes related to late lumen loss after renal 
and femoropopliteal stent implantation. 
METHODS 
The study population comprised the first seven consecutive patients (five men, mean age 
59±10.5 years) treated with balloon expandable Palmaz stents (Cordis Endovascular, a 
Johnson & Johnson Company, Warren, NJ, USA) and studied with IVUS according to a 
protocol approved by the Local Committee on Human Research. Under this protocol. 
renal stenosis patients giving informed consent were studied with IVUS intraprocedurally 
and periodically after stent placement, while consenting patients with femoropopliteal 
stents were evaluated for recurrent symptoms of disabling claudication or for study 
purposes. All patients were known to have angiographically documented >50% diameter 
reduction in the ostial renal artery (n=4) and femoropopliteal segment (n=3). Palmaz 
stents were implanted routinely after pre dilatation in the renal arteries, whereas 
femoropopliteal stents were implanted for suboptimal balloon angioplasty (>50% residual 
stenosis). Operators were not blinded to the IVUS findings during stent implantation. 
Compliant and noncompliant balloons (4-7 mm; OPTA or Powerflex, Cordis Europe, Roden, 
the Netherlands) were used. Anticoagulation was routinely initiated after stent 
placement using aspirin (80 to 100 mg/d) or warfarin (International Normalized Ratio of 
2.0 to 2.5) Angiographically, stent placement was considered successful when a residual 
diameter stenosis <10% was evidenced. On IVUS stent deployment was considered 
successful in case of complete apposition of the stent to the vessel wall and when the 
residual diameter stenosis was <20%.7 
IVUS imaging was performed using a commercially available mechanical system 
containing a single rotating ultrasound element (30 MHz; Endosonics, Rijswijk, the 
Netherlands) with a 0.035-in guidewire tipped, 4.3F flexible catheter (Princeps). Axial 
resolution is 75 I'm and lateral resolution is > 225 11m at a depth of one mm. The unit 
was connected to a prototype instrument that provided continuous real-time 
cross-sections of the vessel wall (up to 16 images/s).' The same imaging technique was 
used immediately after angiographic successful stent placement and at follow-up 
examinations. The IVUS catheter was advanced distally beyond the stented segment and 
cross-sections were obtained during pullback of the catheter. In the femoropopliteal 
arteries, the position of the ultrasound catheter was documented with a radiopaque ruler 
and a displacement sensing device, which consisted of a disposable unit fitted with a 
small wheel that turns simultaneously with movement of the IVUS catheter. 9 
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The resulting images, together with their unique frame number, were displayed on a 
monitor via a video-scanned memory and stored on an S-VHS video system. 
The IVUS images obtained after successful stent placement were compared with the 
corresponding images at follow-up. For the purpose of this study, the cross-sections 
showing the smallest lumen area inside the stent, and both stent edges, obtained at 
follow-up, were matched to the cross-sections derived immediately after successful stent 
placement. Cross-sectional area measurements of the lumen, stent and lesion were 
performed off-line using a computer-based analysis system. 1O Lumen area was defined as 
the area encompassed by the inner boundary of the intimal surface. Stent area was 
defined as the area encompassed by the stent circumference. Lesion area i.e. neointimal 
tissue, seen at follow-up was calculated by subtracting lumen area from stent area. Late 
lumen loss was defined as the difference between the lumen area obtained after stent 
placement and at follow-up. 
The reproducibility of quantitative IVUS parameters has been described previously. II To 
assess the interobserver reproducibility, all matched cross-sections were analyzed by a 
second independent observer (WvL). Interobserver measurements were compared using 
Student's paired t-test. The degree of interobserver variation was presented as a 
coefficient of variation, defined as the standard deviation (SD) of the paired difference 
divided by the mean of the absolute value. All values are given as mean ± SD. A p-value 
<0.05 was considered statistically significant. 
RESULTS 
Stent placement was angiographically successful in all patients. Renal artery stent 
placement was successful on IVUS in all four patients; in one of these patients, a distinct 
lesion distal to the stent seen on IVUS warranted the use of a second overlapping stent 
in order to obtain complete lesion covering. Stent placement in the femoropopliteal 
artery was considered successful on IVUS in all three patients; in one of these patients 
extensive dissection due to balloon angioplasty was solved by placement of overlapping 
stents. 
Six patients were asymptomatic at the time of follow-up angiography and IVUS. In the 
remaining patient treated with overlapping stents in the femoropopliteal artery, 
restenosis was suspected at five months follow-up based on recurrent symptoms; repeat 
angiographic and IVUS examination showed restenosis (diameter stenosis >50%). No 
adverse effect attributable to the use of IVUS was observed in any patient. Follow-up 
angiography in the four patients with renal artery stents was performed at 6, 9, 9 and 12 
months, respectively, while surveillance examinations for the three patients with 
femoropopliteal artery stents were performed at 5, 11, and 34 months, respectively.' 
A total of seven most stenotic sites and 14 stent edges were available for analysis. 
Quantitative data on renal and femoropopliteal artery stents are summarized in Table 1. 
Late lumen loss at the most stenotic site of renal artery stents was less than in 
femoropopliteal artery stents (17% and 62%, respectively). Late lumen loss in renal 
artery stents was mainly due to lesion area increase (3.0±1.3 mm'), while the stent area 
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Table 1. Quantitative intravascular ultrasound data obtained from stents in renat and femoropopliteat 
arteries immediately after stent placement and at follow-up. 
After stent At fonow-up Change 
Femoro- Femoro- Femoro-
Renal popliteal Renal popliteal Renal popliteal 
Most stenotic site (n-4) (n-3) (n-4) (n0 3) (n.4) (n0 3) 
Lumen area (mml) 21.3 ± 6.5 20.7:1:7.7 17.6:1:5.8 7.8 ± 3,5 3.7 ± 3.1 12.8 ± 10.0 
17%1 62%1 
Stent area (nun1) 21.3 ± 6.5 20.7 ± 7.7 20.6 ± 5.9 15.3 ± 5.1 0.7 ± 1.8 5.4 ± 3.6 
3%1 26%1 
Lesion area (mml) 0,0 ± 0.0 0.0 ± 0.0 3.0 ± 1.3 7.4 ± 8.2 '3.0 ± 1.3 17.4 ± 8.2 
Femora- Femoro- Femora-
Renal popliteal Renal popliteal Renal popliteal 
Stent edges (n0 8) (n0 6) (n0 8) (n0 6) (n0 8) (n0 6) 
Lumen area (mm1) 23.3 ± 6.9 20.1 ± 6.3 20.9 :I: 5.7 11.0 ± 2.9 2.4 ± 2.7 9.2 ± 4.2 
10%1 46%1 
Stent area (mml) 23.3 ± 6.9 20.1 ± 6.3 23.5 ± 6.4 16.8 ± 5.6 0.2 ± 1.7 3.4 ± 2.1 
1"10 I 17%1 
Lesion area (mml) 0.0 ± 0.0 0.0 ± 0.0 2.6 ± 1.5 5.8 ± 2.9 12.6 ± 1.5 15.8 ± 2.9 
Values are mean ± SD; I = decrease; 1= increase 
reduced minimally (3%) (Fig. 1). In femoropopliteal artery stents, late lumen loss was 
due to a combination of lesion area increase (7.4±8.2 mm') and stent area reduction 
(26%) (Fig. 1). Both in renal and femoropopliteal artery stents, lesion area increase and 
stent area reduction at the most stenotic site were larger than at the stent edges. In 
addition, in two patients with femoropopliteal artery stents located in the adductor 
canal, elliptical deformation of the stent was seen at the distal stent edge. 
Normal distribution of all analyzed data was evidenced. There was no significant 
interobserver difference for lumen area after stent placement and at follow· up 
(+O.43±1.06 mm' and -O.Ol±O.66 mm', respectively). The interobserver difference for 
stent area at follow-up (+O.76±O.96 mm') was significant (p=O.002). The coefficient of 
variation for lumen area after stent placement and at follow-up was 4.9% and 4.3%, 
respectively. For stent area at follow-up the coefficient of variation was 4.9%. 
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Figure 1. Intravascular ultrasound cross-sections after stent implantation (left panel) and at foHow-up 
(right panel) of the renal artery (A) and femoropopliteal artery (B), Lumen area (inner contour) and stent 
area (outer contour) display quantitative results. A, late lumen loss is minimal and solely due to 
neointirnal tissue proliferation. B, both neointimal tissue proliferation and stent area reduction contribute 
to late lumen loss at follow-up. 
DISCUSSION 
In a similar fashion to previous IVUS investigations in coronary and lower limb arteries,"s 
our study has shown that the mechanisms for and extent of late lumen loss may differ in 
renal and femoropopliteal stents, In the renal arteries we interrogated, intimal 
hyperplasia was minimal at the most stenotic site within the stent and at the stent 
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edges (an 11% to 14% decrease from the initial stent lumen diameter). However, in 
femoropopliteal stents, neointimal proliferation was twice as exuberant (29% to 35% late 
lumen loss), comparable to that reported in coronary arteries (30%).l,I2 
A remarkable observation in the present IVUS study was the stent area reduction 
encountered in the femoropopliteal artery stents (mean 26% decrease at the most 
stenotic site, 17% at the stent edges). This loss was due not only to a decrease of stent 
circumference at the most stenotic site but also to elliptical deformation at the adductor 
canal in two of three distal stent edges at the adductor canal (contributing for 11% and 
45% to the late lumen loss, respectively). Rosenfield et al. 5 reported stent compression 
and neointimal tissue proliferation as the major causes of restenosis in femoropopliteal 
stents, but they did not mention elliptical deformation. 
In a similar fashion to reports for coronary stents,3.4 our IVUS study did not document 
significant stent area reduction in renal stents. However, our observations do not agree 
with the quantitative angiographic data of Khosla et al.,13 who reported that tissue 
ingrowth (15 to 19%) and stent recoil (25-42%) contributed to the late lumen loss six 
months after renal artery stenting. This discrepancy may be due to a phenomenon, 
alluded to by Hoffmann et al.," that quantitative coronary angiography significantly 
overestimates the initial stent lumen diameter compared to IVUS. The authors postulated 
that contrast flow around the stent struts immediately after stent deployment may 
increase the stent lumen diameter measurable on the angiogram. Consequently, a falsely 
elevated stent area reduction might be seen at follow-up with quantitative angiographic 
measurements, which could explain the stent recoil observed by Khosla et al. 
In our admittedly small sample, overlapping stents in the renal artery did not result in 
restenosis at follow-up, a feature found to be responsible for the restenotic process in 
femoropopliteal artery stents.6 However, no reliable comments on or comparisons of 
restenosis rates between renal and femoropopliteal stents can be made based on these 
limited observations. At present, we routinely deploy stents when we treat renal 
atherosclerotic lesions according to protocol in an ongoing trial. Conversely, we do not 
commonly use stents in the femoropopliteal segment~ as recommended by Henry et al. 15 
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Prospectively, 38 patients who 
underwent stent placement for 
symptomatic renal artery 
stenosis Ylere studied with 
intravascular ultrasound 
(IVUS) and angiography after 
stenting and at one-year 
follow-up. At follow-up, IVUS 
showed a significant lumen 
area decrease in the stent 
solely due to plaque 
accumulation. At the distal 
main renal artery, lumen area 
decreased significantly solely 
due to vessel area decrease; 
this was confirmed 
angiographically. Clinically, 
blood pressure, and number of 
antihypertensive medications 
were significantly decreased 
and serum creatinine 
concentrations remained stable. 
In conclusion, renal artery 
stent placement is followed by 
unexplained shrinkage of the 
distal main renal artery. 
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Stent placement is in common use for the revascularization of renal artery stenosis 
(RAS). However, restenosis after renal artery stent placement continues to be a problem, 
with reported restenosis rates in up to 39% of patients at eight months follow-up.' In 
order to characterize the restenotic process we used intravascular ultrasound (IVUS), as 
an adjunct to standard angiography, because IVUS provides accurate data on vessel and 
plaque dimensions that allow to monitor changes that occur over time in the treated 
vessel. 
The aim of the present study was to determine the quantitative IVUS and angiographic 
changes in the renal artery seen at one-year follow-up, together with the clinical 
outcome in a series of consecutive patients who underwent renal artery stenting for 
atherosclerotic RAS. 
METHODS 
Patients 
Between September 1996 and December 1998, 41 consecutive patients (27 men, 14 
women; aged 60 ± 9 years [mean ± SD]) presenting with symptomatic RAS of >50% 
diameter stenosis were treated with stent placement. One patient underwent stenting of 
both renal arteries on two separate occasions; thus, a total of 42 renal arteries were 
treated. Patients had renal function impairment (serum creatinine >110 llmol/l; n~26) 
and/or drug resistant hypertension, defined as a diastolic blood pressure >95 mmHg 
while receiving two "defined daily doses" of antihypertensive drug treatment (n=26; 
DDDs; the DDD is the assumed average maintenance doses of the individual drugs based 
on its main indication in adults).2 Patients were studied with IVUS and angiography 
before any intervention was performed and immediately after stent placement. During 
follow-up, patients returned to the outpatient clinic. Blood pressure, the amount of 
antihypertensive drugs prescribed, and serum creatinine concentrations were monitored. 
If possible, the type of antihypertensive medication was held constant during the 
follow-up period. At one-year follow-up IVUS and angiographic examinations were 
repeated. The Local Committee on Human Research approved the investigation. Written 
informed consent was obtained from all patients. 
Procedure 
Pre-intervention digital subtraction angiograms were obtained using aortic-flush 
injections. The stenosis was then crossed with a 5F selective catheter. Pre-intervention 
IVUS imaging was performed over a 0.020-in flexible tip guide wire (Boston Scientific, 
Ireland). The lesion was predilated with an angioplasty balloon five or six mm in 
diameter. A Palmaz stent (Johnson & Johnson Interventional Systems, New York, USA) 
was then placed (p104, p154 or p204 stents). The stent placement was considered 
technically successful when post-procedural IVUS and angiography showed complete 
stent-vessel wall apposition, complete lesion covering, and a <20% residual diameter 
stenosis.) When necessary, additional stent dilatation was performed using a six or seven 
mm balloon. During the procedure, the patients received 5,000 IU of heparin, after which 
heparin infusion was continued for 48 hours (20,000-30,000 IU per day). 
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Oral acetylsalicylic acid (100 mg daily) was started at the day of the procedure and 
continued during the entire follow-up period_ 
lVUS analysis 
For rvus examination, a 30 MHz mechanical imaging system ("Princeps", Endosonics, 
Rijswijk, The Netherlands)' with 4.3F catheters was used. The IVUS catheter was 
positioned distally from the stenosis in a second-order renal artery branch. Real-time 
cross-sectional images of the entire main renal artery, obtained during slow pullback of 
the IVUS catheter, were displayed on a monitor and stored on S-VHS videotape. For the 
purpose of this study quantitative analysis was performed. Before intervention, a 
reference cross-section of the distal renal artery just proximal to the first major 
side-branch was analyzed. 
After stent placement At one-year foHow-up 
Figure 1. Intravascular ultrasound and angiographic images after stent placement (A and B) and at 
one-year follow-up (C and D). The inner contour of the intravascular images presents the lumen area; the 
outer contour the stent or vessel area. At follow-up plaque accumulation was evidenced in the stent (C) 
whereas the distal reference cross-section (D) showed shrinkage without plaque accumulation. 
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In addition, after IVUS and angiographic successful stent placement and at one-year 
follow-up three cross-sections selected from the IVUS examinations were analyzed: one 
cross-section at the most stenotic site in the stent and two reference cross-sections in 
the distal renal artery (one just distal to the stent and another just proximal to the first 
major side-branch). Analysis included assessment of the lumen area (LA; the area 
encompassed by the inner intimal surface), the native vessel area (VA; the area bounded 
by the external elastic lamina), the stent area (SA; the area encompassed by the stent 
struts), and the plaque area (PLA; calculated as VA minus LA, or SA minus LA for the 
stented and non-stented cross-sections, respectively). All IVUS measurements were 
performed by two independent observers; mean values of the two observers are given. 
Angiographic analysis 
Angiographic in-stent restenosis at one-year follow-up was defined as a >50% diameter 
reduction in the stent, compared to the distal distal main renal artery. After stent 
placement and at follow-up, angiographic lumen diameter of the ipsi- and contralateral 
main renal arteries (before the first major side-branch) and of major intrarenal branches 
were quantified in an absolute sense by relating the measurements to the known length 
of the Palmaz stent. In addition, the angiographic diameter of the affected renal artery 
distal to the lesion before and immediately after stent placement and at follow-up was 
expressed as a percentage of the diameter of the contralateral renal artery. 
Clinical outcome 
Systolic and diastolic blood pressure measurements obtained before and immediately 
after stent placement and at one-year follow-up were compared. In addition, the amount 
of antihypertensive drugs and serum creatinine concentrations were compared before 
intervention and at one-year follow-up. Clinical outcome for blood pressure and renal 
function was determined for the subgroups of patients with hypertension or renal 
function impairment. 
Statistical analysis 
Observer variability for IVUS measurements was analyzed using regression analysis and 
Bland-Altman's method. Student's t-test for paired observations was used to test for 
significant differences between measurements at baseline, after stent placement and at 
follow-up. Furthermore, we assessed whether there was a relation between procedural 
(i.e. stent length), IVUS and angiographic data and the clinical outcome. Relationship 
between categorical variables was demonstrated in contingency tables using the 
chi-squared test. Categorical variables included stent length, angiographic lesion location 
(ostial or truncal'), and angiographic stent patency. Relationship between categorical 
and continuous variables was assessed using Student's t-tests. For continuous variables 
Pearson's correlation coefficient was calculated using SPSS for Windows (version 9.0). 
Correlation coefficients were determined between the percentage change in vessel area of 
the distal renal artery and the change in systolic or diastolic blood pressure. Correlation 
coefficients were considered worth mentioning in case of r values >0.50. A p-value <0.05 
was considered statistically significant (two-sided). 
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RESULTS 
Stent placement was technically successful in 39 renal arteries of 38 patients. At baseline 
IVUS was performed in 14 patients and after stent placement in 38 patients. In the 
remaining patients, the IVUS catheter could not pass the stenosis, or the interventionist 
refrained from using IVUS before stent placement. Follow-up (12.2 ± 2.8 months [mean ± 
SD]) IVUS imaging was completed in 30 renal arteries of 29 patients. In one patient the 
IVUS catheter could not pass the stent. Angiography before and after stent placement 
was obtained in all 38 patients and in 28 patients at follow-up: in two patients with poor 
renal function angiography was not performed. Eight patients were lost to follow-up 
(dialysis n=3; patient refusal n~4; patient death n~l). Stent patency was demonstrated 
in the latter patients during follow-up with spiral CT or captopril renography. 
Angiographic in-stent restenosis was encountered in four of 28 patients (14%) and these 
patients underwent additional balloon angioplasty. 
Lumen area in the stent decreased significantly during follow-up from 24 ± 5.6 mm' to 
17 ± 5.6 mm' (p<0.001; Table 1), which was entirely due to an increase of plaque area in 
the stent; the stent area (and the stent diameter) remained unchanged. In the renal 
artery distal to the stent, the lumen area decreased significantly due to a decrease in 
vessel area (39 ± 14.0 mm' immediately after stent placement to 29 ± 9.3 mm' at 
follow-up; p<O.OOl; Fig. 1) without plaque accumulation. Of all reference cross-sections after 
stent placement, 42 showed a vessel a,ea decrease, 11 showed a less than 10% change, and 
seven showed an enlargement. Of 10 patients with matched pre·intervention and follow·up 
IVUS data, the reference vessel area at follow·up was smaller (>10%) than before any 
intervention was performed in five patients, had less than 10% change in two patients, 
Table 1. Intravascular ultrasound measurements in 30 renal arteries obtained 
immediately after stent placement and at one·year foHow-up. Cross-sections were 
analyzed at the most stenotic site in the stent and at two reference sites distal to 
the stent in the main renal artery (n=60). 
After stent 
placement Follow-up 
(mml) (mm!) p-va\ue 
Stent Lumen area 24 ± 5.6 17 ± 5.6 <0.001 
Stent area 24 ± 5.6 25 ± 5.5 NS 
Plaque area 0 7 ± 4.0 <0.001 
Main fenal artery Lumen area 29±11.4 20 ± 7.3 <0.001 
Vessel area 39 ± 14.0 29 ± 9.3 <0.001 
Plaque area 10 ± 4.7 10 ± 4.4 NS 
Values are mean ± SO; NS = Not signiHcant. 
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and was larger (>10%) in three patients. There was good observer agreement for rvus 
measurements, with a high correlation coefficient (r=O.978; obselVer-2 ~ 0.99 * obselVer-l - 0.01) 
and an overall coefficient of variation of 6.3%. 
Similar to the rvus measurements, quantitative angiographic measurements of the distal 
main renal artery showed a significantly decreased diameter at one-year follow-up when 
compared to diameters measured immediately after stent placement (p<0.001; Table 2). 
In contrast, the diameter of the intrarenal branches and the contralateral renal artery 
diameters remained unchanged. Whereas immediately after stent placement there was no 
significant difference between the diameter of the ipsi- and contralateral renal arteries, 
the treated renal artery at follow-up was significantly smaller than the contralateral 
artery (5.0 ± 1.4 mm vs. 5.8 ± 1.2 mm, respectively; p~0.004). The distal renal artery 
diameter at follow-up was also significantly smaller than before stent placement (86 ± 
5.1% [mean ± SEM] vs. 104 ± 5.3% of the contralateral renal artery diameter; p~0.003; 
Fig. 2). 
Table 2. Angiographic measurements obtained immediately after stent placement and at one-year 
follow·up (n=28). 
After stent 
placement FoUow-up 
(mm) (mm) p-value 
Treated renal artery Main renal artery 6.5 ± 1.4 5,0 ± 1.4 <0.001 
Intrarenal branch 2.7 ± 1.0 2.8 ± 0.7 NS 
Contralateral lenal artery Main lenal artery 6.1 ± 1.3 5,8 ± 1.2 NS 
IntTarenal branch 3.0 ± 1.0 2.9 ± 0.8 NS 
Values are mean ± SD; US "" Not significant. 
In patients treated for hypertension (n~22), systolic blood pressure was decreased 
immediately after stent placement (180 ± 17.4 to 130 ± 46.5 mmHg; p~O.OOl) and 
remained significantly decreased at one-year follow-up (151 ± 22.4 mmHg; p<O.OOl). The 
same applies to diastolic blood pressure, which decreased immediately after stent 
placement (103 ± 6.7 to 74 ± 25.1 mmHg; p~0.002) and at follow-up was significantly 
decreased compared to pre-intervention values (86 ± 9.5 mmHg; p<O.OOl). Similar to the 
decrease of blood pressure, there was a significant decrease in the number of 
antihypertensive medications used at one-year follow-up (3.8 ± 1.80 to 2.6 ± 2.11 DDDs; 
p~O.OOl). In patients treated for renal failure (n~13), serum creatinine values remained 
stable (150 (134) llmol/l [median (range)] to 131 (334) llmol/l; p~NS). 
In the subgroup of patients treated for hypertension, the percentage vessel area decrease 
in the distal renal artery was significantly associated with the decrease in systolic blood 
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pressure at follow-up (r-0_50; p=0.032). No relationship was found between procedural 
and angiographic data and the changes in IVUS and clinical parameters. 
DISCUSSION 
In the present study we quantified the change in vessel dimensions of the renal arteries 
during the first year after stent placement for atherosclerotic RAS. At one-year follow-up 
there was a significant decrease in lumen area in the stent, which was solely due to 
plaque accumulation. There was no evidence for recoil of the Palmaz stent which agrees 
with findings reported in coronary stents;' however, the typical plaque accumulation at 
the stent edges, as reported in coronary stents.' was not seen in renal stents. The 
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Before stent After stant At follow-up 
placement placement 
Figure 2. Renal vessel diameter (RVD) ofthe affected 
side before and after stent placement and at 
foHow-up expressed as percentage of the contralateral 
artery diameter. The relative diameter at foHow-up 
was significantly smaller than pre-interventionat 
values. Mean ± SEM are indicated. 
in-stent restenosis rate of 14% in the present study was similar to the 19% restenosis rate 
reported in a series of 100 renal stent patients by White et aI.' It should be acknowledged that 
the favorable restenosis rate in the present study may be related to the use of IVUS during the 
stent placement procedure: in 33% of the patients additional dilatation or stent placement was 
warranted to achieve accurate stent placement. However, a randomized study is required to 
assess the true beneficial role of IVUS on the long-term stent patency. 
A remarkable finding in the present study was shrinkage of the affected distal main renal 
artery without plaque accumulation at follow-up. The absolute vessel area as measured with 
IVUS decreased by 25%. This shrinkage was also evidenced with angiography and was limited to 
the main renal artery distal to the stent. At angiography the diameter of the affected main 
renal artery (compared to the contralateral renal artery) at follow-up was significantly smaller 
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than immediately before and after stent placement. To the best of our knowledge, this 
shrinkage has not been described before. At present, there is no clear explanation for this 
phenomenon, and the following discussion is therefore speculative. 
A potential explanation for shrinkage may be found in the change of blood flow due to stent 
placement. Stent placement is reported to cause an increase in blood flow in the distal main 
renal artery.' Increased blood flow will increase the wall shear stress (wall shear stress = 
4*blood viscosity*flow/m'). Increased wall shear stress will induce an adaptation process of the 
vessel wall mediated by nitric oxide,1O which may result in vessel dilatation both immediately 
after stent placement and at follow-up. After stent placement, this agreed with data presented 
previously and with our previously presented findings that pre dilatation and stent placement 
resulted in enlargement of the distal renal artery.'·s At follow-up, however, we experienced 
shrinkage of the distal renal artery instead of a dilatation. 
On the other hand, long-term data on blood flow after stent placement are scarce and it is not 
clear whether renal artery stenting results in long-standing flow improvement. Since a kidney 
regulates blood flow by changing vascular resistance, an initial increase of renal vessel 
dimensions may be explained as a lack of immediate adaptation to increased blood flow. On the 
long-term, the kidney may have adapted its vascular resistance, which might have resulted in a 
decrease of renal blood flow, thereby decreasing the renal vessel dimensions. 
The decrease in renal vessel diameter may also reflect an active shrinkage process. This may be 
due to iatrogenic damage to the renal artery segment inunediately distal to the stent during 
stent placement. It has been previously reported that such stretching of the vessel wall in 
coronary arteries may cause injury with fragmentation of the internal elastic lamina, resulting 
in neointimal thickening at follow-up.ll In the present study, however, shrinkage occurred 
without neointimal thickening; also it occurred in the distal renal artery segment, unlikely to 
be touched by the dilatation balloon. 
Clinical results for blood pressure were favorable and renal function stabilized. The 
encountered shrinkage seemed to have clinical implications in that the extent of vessel 
shrinkage was associated with the extent of decrease in systolic blood pressure at follow-up. 
Possible (patho )physiologic mechanism underlying these findings, however, should be 
determined in future studies. Aside from measurements of renal blood flow before and 
immediately after stent placement and at follow-up, it would be of interest to study whether 
shrinkage is associated with endothelial dysfunction or is a more generalized reflection of 
vascular pathology. This may be determined by measuring the vasodilative capacity of the 
distal renal artery after infusion of endothelial-dependent and - independent substances, e.g., 
by using Doppler flow-wires. 
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To study the effect of stent 
placement for renal artery 
stenosis on the function of the 
treated and contralateral kidneys, 
18 patients underwent renal vein 
blood sampling before 
angiography and stent placement 
and at one-year follow·up, after 
constant systemic infusion of 
H1I-hippuran and 1l5I-thalamate. 
"!his allowed assessment of the 
single-kidney contributions to the 
total renin secretion, effective 
renal plasma flow (m I-hippuran 
clearance) and glomerular 
filtration rate ("'Hllalamate 
clearance). Analysis showed that 
renal artery stenting was capable 
of causing longstanding 
improvement of renal blood flow 
and glomerular filtration rate of 
the treated kidney, and 
disappearance of renin 
suppression of the contralateral 
kidney. 
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Renal artery stenosis (RAS) due to atherosclerosis is a progressive disease that may 
ultimately lead to renal artery occlusion and loss of renal function. Revascularization of 
symptomatic RAS is thought to be beneficial by improving the function of the affected 
kidney or, at least, halting the progressive loss of renal function. Revascularization by 
stent placement is now well accepted as part of the treatment of atherosclerotic RAS. 
Clinical experience has shown that renal artery stenting may improve overall renal 
function in some but not all patients.' To explain this heterogeneous response, hard data 
on the physiological effects of stent placement, especially on the treated kidney, are 
required. Such data, however, are scarce due to the difficulty of evaluating the function 
of the left and right kidneys separately. 
The aim of this study was, therefore, to determine the separate effects of renal artery 
stent placement on the treated and untreated contralateral kidney rather than on the 
overall renal function. For this purpose, we determined the single-kidney vein-to-artery 
ratios of renin and extraction ratios of 1l1j-hippuran and 125j-thalamate prior to stent 
placement and at one-year follow-up in conjunction with measurements of the 
two-kidney clearances of "'j-hippuran (effective renal plasma flow) and 125j-thalamate 
(glomerular filtration rate). 
METHODS 
Patients 
The study group comprised 18 patients (12 males, 6 females; aged 56 ± 10.7 years [mean 
± SD]) who underwent stent placement for angiographically proven symptomatic 
unilateral atherosclerotic renal artery stenosis of > 50% luminal diameter reduction and 
were studied by means of renal vein blood sampling. These patients were selected from a 
group of 40 consecutive patients undergoing stent placement who were referred to our 
hospital in the years 1997 and 1998. The length of the treated kidney, as determined by 
ultrasound, was> 8 em in all patients. Renal scintigraphy with mercaptoacetyltriglycine 
(MAG,) and other single-kidney renal function studies were performed within one month 
before stent placement. These tests were repeated one year after the procedure, prior to 
the angiographic follow-up examination. Medication regimen and blood pressure were 
recorded before intervention and at follow-up. The study protocol was approved by the 
Local Committee on Human Research and written informed consent was obtained from all 
patients. 
Renal scintigraphy 
Scintigraphy was performed with the patient in the supine position and using the 
posterior view. Patients received 25 or 50 mg of captopril orally at one hour before the 
examination. After intravenous administration of 74 MBq "rnTc-MAG" data were collected 
in 10-second frames during a 20-minute period. The number of total counts accumulated 
in the kidney during the first 60 seconds were quantified and were taken as a measure of 
the renal plasma flow to the affected and contralateral kidneys. This method is based on 
the assumption that the early part of the time-activity curve is determined solely by the 
renal plasma flow. 
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Renal vein blood sampling 
Concentrations of active renin and 131I-hippuran and 125I-thalamate in the left and right 
renal veins were measured and assayed as described by Wenting et al.' The method 
involves constant infusion of lllI-hippuran and 125I-thalamate through an antecubital 
vein. After reaching the steady state, a renal venous blood sample was taken at each side 
simultaneously with a sample from the abdominal aorta. Samples from these sites were 
also used for renin measurements. Additional blood samples were taken at i5-minute 
intervals from a peripheral vein to estimate the total (two-kidney) clearances of 
lllI-hippuran and 125I-thalamate. All blood samples were immediately centrifuged and 
measurements were made in plasma. Determination of blood oxygen saturation served to 
assure that blood samples were taken from the renal veins. Single-kidney extraction 
ratios of lllI-hippuran and "'I-thalamate were defined as (A-V)/ A, where A = activity in 
the abdominal aorta and V = activity in renal vein. The total clearances of lllI-hippuran 
and 125I-thalamate were taken as a measure of total effective renal plasma flow (ERPF) 
and glomerular filtration rate (GFR), respectively. The concentration of active renin in 
plasma was measured by radioimmunoassay.] The normal value of the vein-to-artery ratio 
of renin is 1.24. In case of renal artery stenosis, the vein-to-artery ratio at the treated 
side is considered elevated with values >1.48. Contralateral suppression of renin 
secretion is defined as a vein-to-artery renin. ratio <1.13.' 
Stent placement 
Pre-intervention digital subtraction angiograms were obtained using aortic-flush 
injections. The stenosis was then crossed with a 5F selective catheter and the lesion was 
predilated with an angioplasty balloon. A Palmaz stent (Cordis, Johnson & Johnson 
Interventional Systems, New York) was placed, and the procedure was considered 
technically successful when both intravascular ultrasound and angiography showed 
complete stent-vessel wall apposition, complete lesion-covering, and <20% residual 
diameter stenosis.' If necessary, additional stent dilatation was performed. During the 
procedure the patients received 5,000 IU of heparin, and heparin infusion was continued 
for 48 hours (20,000-30,000 IU per day). Oral acetylsalicylic acid (100 mg daily) was 
started at the day of the procedure and continued during the entire follow-up period. 
Calculations 
Two-kidney ERPF was calculated by dividing the infusion rates of lllI-hippuran by the 
peripheral venous plasma concentration of 131I-hippuran. Similarly, two-kidney GFR was 
calculated by dividing the infusion rate of 125I-thalamate by the peripheral venous plasma 
concentration of 125I-thalamate. In addition, single-kidney RPF, ERPF and GFR were 
calculated by using single-kidney data derived from MAG]-scintigraphy as explained in 
the Appendix. 
Statistical analysis 
The effect of intervention on single-kidney function parameters was analyzed using 
Student's paired t-tests at p<0.05. Analysis was repeated for the subgroup of patients 
(n=9) who used the same medication both pre-stenting and after one year, to test 
whether differences in medication had influenced the results. 
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RESULTS 
Stent placement was angiographically successful in all patients. Angiography at 
follow-up (12 months in 16 patients and six months in two patients) showed restenosis 
> 50% (compared to the distal main renal artery diameter) in four patients. 
At follow-up, the renal vein-to-artery renin ratio at the treated side had decreased from 
1.65 ± 0.131 to normal, 1.23 ± 0.076 ([mean ± SEMj; p=0.009; Table 1). Contralaterally, 
the vein-to-artery renin ratio was 1.09 ± 0.042 before stenting and 1.17 ± 0.029 at 
follow-up (p=NS). Peripheral renin values decreased significantly from 251 ± 114.0 ng 
Angiotensin I/ml per hour before stenting to 94 ± 55.1 ng Angiotensin I/ml per hour at 
one-year follow-up (p=0.046). 
Table 1. Measured single-kidney function parameters obtained before stent placement and at one-year 
follow-up in 18 patients. 
Before stent 
placement At follow-up p-value 
Vein-ta-artery renin ratio Treated 1.65 ± 0.131 1.23 ± 0.076 0.009 
Contralateral 1.09 ± 0,042 1.17 ± 0.029 NS 
Aortic renin concentration, 251 ± 114.0 94 ± 55.1 0.046 
ng Ang Jlmt per hour 
Extraction ratio IIII-hippuran Treated 0.48 ± 0.049 0.62 ± 0,034 0.006 
Contralateral 0.67 ± 0.033 0.73 ± 0.026 NS 
Extraction ratio of I!5Hhalamate Treated 0,12 ± 0.014 0.17 ± 0.012 0.002 
Contralateral 0.18 ± 0.013 0,22 ± 0.011 0.015 
Two-kidney ERPF, m1jmin 323 ± 23.1 333 ± 27.8 NS 
Two-kidney GFR, m1jmin 76 ± 7.2 77 ± 7.8 NS 
Values are mean ± SEM; ERPF '" Effective renal plasma flow; GFR '" Glomerular filtration rate. 
The renal extraction ratios of IllI-hippuran improved at the treated side (0.48 ± 0.049 to 
0.62 ± 0.034; p=0.006) and did not change contralaterally (0.67 ± 0.033 to 0.73 ± 0.026; 
poNS). The extraction ratio of l"I-thalamate, which equals the filtration fraction, 
improved at both sides (0.12 ± 0.014 to 0.17 ± 0.012 at the treated side; p=O.002; and 
0.18 ± 0.013 to 0.22 ± 0.011 contralaterally, respectively; p=0.015). 
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Total (two-kidney) ERPF did not change (323 ± 23.1 to 333 ± 27.8 mt/min; p=NS). The 
same was true for the total effective renal blood flow (575 ± 45.6 to 564 ± 66.7 mt/min; 
p=NS). Total GFR also did not change (76 ± 7.2 to 77 ± 7.8 mt/min; p=NS). 
Table 2. Calculated single·kidney function parameters obtained before stent placement and at 
one-year follow·up in 18 patients. 
Before stent 
placement At fonow-up 
Flow raHo 
t reate dl contralateral 0.85 ± 0.105 0,89 ± 0.110 
RPF, mlfmin Treated side 212 ± 19.8 226 ± 24.5 
Contralateral side 342 ± 33,2 284 ± 22.2 
ERPF, m1fmin Treated side 106 ± 15.6 136 ± 15.4 
Contralateral side 213 ± 19.4 227 ± 19,2 
GFR, rot/min Treated side 27 ± 4.5 38 ± 4.7 
Contralateral side 59 ± 7.1 64 ± 6.4 
Values are mean ± SEM; RPF '" Renal plasma flow; ERPF = Effective renal plasma flow; 
GFR", Glomerular filtration rate. 
p-value 
NS 
NS 
0.023 
0.057 
NS 
0.022 
NS 
Calculated RPF of the treated kidney was 226 ± 24.5 mt/min before stent placement and 
212 ± 19.8 mt/min at one-year follow-up (p=NS; Table 2). Calculated RPF of the 
contralateral kidney decreased significantly from 342 ± 33.2 to 284 ± 22.3 mt/min 
(p=0.02). Calculated ERPF of the treated kidney was 106 ± 15.6 mt/min before stenting 
and 136 ± 15.4 mt/min at follow-up (p=0.057). Calculated ERPF of the contralateral 
kidney was 227 ± 19.2 mt/min before stenting and 213 ± 19.4 mt/min at follow-up 
(p=NS). The flow improvement of the treated kidney, indicated by these calculations, are 
in agreement with the normalization of the renal vein-to-artery renin ratio of the treated 
kidney. Calculated GFR of the treated side rose significantly from 27 ± 4.5 to 38 ± 4.7 
mt/min (p=0.022) and did not change contralaterally (59 ± 7.1 to 64 ± 6.4 mt/min; 
p=NS). 
Finally, the conclusions of the analysis in the subgroup of patients (n=9) with 
unchanged medication regimen were consistent with those of the entire patient group. 
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DISCUSSION 
Evaluation of the effect of renal artery stent placement on renal function is hampered by 
limited data on the function of the kidneys separately. In the present study 
single-kidney function was determined before and one year after renal artery stent 
placement. 
We found a decrease in the vein-to-artery renin ratio of the treated kidney and an 
increase contralaterally. This finding extends previous studies on the effects of balloon 
angioplasty without stenting, which reported that the lateralization of renin secretion to 
the stenosed kidney together with contralateral suppression had normalized 6-39 months 
after the procedure.'" Under steady state conditions, an increased vein-to-artery renin 
ratio of a kidney perfused by a stenosed renal artery is a reflection of decreased renal 
blood flow rather than increased renin secretion. Consequently, the normalization of the 
vein-to-artery renin ratio we observed after one year primarily reflects a lasting increase 
of blood flow to the treated kidney. We observed a decrease in aortic renin 
concentration, which indicates a decrease of the two-kidney release of renin. Since, 
before the intervention, renin release of the contralateral kidney was suppressed, the 
observed change in arterial renin levels can be considered as evidence indicating a 
decrease in renin release by the treated kidney. 
Data on single-kidney function measurements before and after renal artery stent 
placement are, to the best of our knowledge, not available in the literature. The present 
study shows that the extraction ratios of I3II-hippuran and '15I-thalamate of the treated 
kidney improved at one-year follow-up. Before intervention, the extraction ratio of 
ll'I-hippuran was impaired, which is in accordance with the literature.' This may be 
explained by a redistribution of renal blood flow in the presence of a renal artery 
stenosis in such a way that the sites where ll'I-hippuran is excreted by the tubules are 
bypassed. An alternative explanation is a reduction in urine flow resulting in some 
tubular reabsorption of ll'I-hippuran. The increase in 125I-thalamate extraction of the 
treated kidney reflects an increase of filtration fraction and, probably, due to an increase 
in GFR. 
So far, we discussed our data in semiquantitative terms. In order to obtain quantitative 
information, we made use of calculations of single-kidney RPF, ERPF and GFR on the 
basis of the court-ratio (treated/contralateral kidney) as derived from the MAG, 
time-activity curve. The implicit assumption was that the extraction ratios of the 
intravenously infused radiofarmacon were not different between the treated and 
contralateral kidney. This study, however, shows that the extraction ratio of 
'3II-hippuran at the treated side was smaller than contralaterally. Therefore, our 
calculated data underestimated the true renal plasma flow of the treated kidney and, 
consequently, the GFR of the treated kidney. It should be noted here, that 
MAG,-scintigraphy was performed with captopril challenge and this is known to reduce 
the extraction ratio of I3II-hippuran.' However, the direction of changes as shown by our 
calculations is in agreement with the conclusions derived from the renin measurements. 
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The two sets of data showed an increase of ERPF and GFR after stenting at the treated 
side. We found that the total GFR was unchanged, which may be explained by the fact 
that differences in function of the contralateral kidney counterbalanced the beneficial 
effect on the treated kidney. Our finding that the filtration fraction of the contralateral 
kidney was increased after stent placement, suggests a proportionally larger decrease in 
RPF than in GFR. This was in agreement with the calculated data of the contralateral 
kidney. 
Although renal artery stent placement resulted in improvement of renal function in the 
patient group as a whole, on individual basis there was a wide range of responses. This 
may have been caused by restenosis or by progressive renal disease. We found no 
significant differences in single-kidney function data between the patients with and 
without restenosis. Our analysis, however, was limited to a small group of patients. 
Some other limitations of the present study should also be addressed. First, serial 
single-kidney measurements were available in only 18 of the 40 patients. This may have 
caused a selection bias. Second, as explained above, the renal blood flow measurements 
derived from MAG,-scintigraphy should be interpreted with caution. Third, the 
single-kidney measurements may have been influenced by the medication used at the 
time of renal vein blood sampling. This, however, seems less likely since the conclusions 
derived from the analysis in patients with unchanged medication were consistent with 
those derived from the entire patient group. 
In conclusion, renal artery stent placement is capable of causing longstanding 
improvement of blood flow and glomerular filtration rate of the treated kidney and leads 
to disappearance of renin suppression of the contralateral kidney. These results also 
illustrate that single-kidney function measurements may provide information on the 
effects of stent placement that cannot be obtained by conventional renal function 
measurements. 
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APPENDIX 
The renal plasma flow of the treated side (RPF,,) and eontralaterally (RPF,,), 
the effective renal plasma flow of the treated side (ERPF,,) and eontralaterally (ERPF,,), 
together with the glomerular filtration rate of the treated side (GFR,,) and 
eontralaterally (GFR,,) were calculated as follows: 
Extraction ratio of 131I-hippuran (Ehip) = effective renal plasma flow / renal plasma flow; 
Extraction ratio of 125I-thalamate (Ethal) = glomerular filtration rale / renal plasma flow. 
The extraction ratios can be written as follows: 
RPF" = ERPF" / Ehip" (1) 
RPF" = ERPF" / Ehip" (2) 
GFR. = RPF" • Elhal" (3) 
GFR" = RPF" • Ethal" (4) 
In which the suffices hi and 'el' stand for the treated and contralateral side, respectively. 
The renal plasma flow ratio belween Ihe Iwo kidneys is given by: 
RPF" / RPF" = Floweounls" / Floweounts" (5) 
In which Floweounts = the area of Ihe time-aetivily curve during the first 60 seconds, 
Ihereby assuming Ihal Ihis part of the curve is delermined solely by Ihe renal plasma flow. 
From equations (1), (2) and (5), il follows Ihal: 
ERPF., / ERPF" = (Ehip" / Ehip,,) • (Floweounts" / Floweounls,,) (6) 
Tolal effective renal plasma flow is defined as: 
ERPF" + ERPF" = tolal C-hip (7) 
In which lotal C-hip = lotal clearance of IlII-hippuran. 
From equations (1), (2), (5), (6) and (7) il follows Ihal: 
RPF" = Floweounts" • tolal C-hip / (Ehip" • Floweounls" + Ehip" • Floweounls,,) (8) 
RPF" = Floweounts" • tolal C-hip / (Ehip" • Floweounls" + Ehip" • Floweounls,,) (9) 
From equations (1), (2), (8) and (9) il follows Ihal: 
ERPF" = Floweounls" • Ehip" • 10lal C-hip / (Ehip" • Flowcounls" + Ehip" • Floweounlsd ) (10) 
ERPFcl = Floweounls" • Ehip" • lolal C-hip / (Ehip" • Floweounl", + Ehip" • Floweounlsd) (11) 
From equations (3), (4), (8) and (9) il follows Ihal: 
GFR. = Floweounls" • Etha~, • lolal C-hip / (Ehip" • Floweounl", + EhiPd • Floweounts,,) (12) 
GFRct = Floweounls" • Elhalct • lolal C-hip / (Ehip" • Floweounls" + Ehip" • Floweountsd ) (13) 
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To identify pre-intervention 
parameters that predict one-
year clinical outcome of stent 
placement for renal artery 
stenosis, regression analysis 
was performed using 
anatomical parameters from 
angiography and in"travascu[ar 
ultrasound and junctional 
parameters from single-kidney 
renal function tests and renal 
scintigraphy as independent 
variables. Clinical success of 
renal artery stent placement at 
one-year follow-up was better 
in patients treated for 
hypertension than for renal 
function impairment (85% and 
35% of the patients, 
respectively). In the latter 
group, lateralization to the 
affected kidney on the 
scintigram appeared to be a 
positive predictor of clinical 
success. 
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PREDICTORS FOR CLINICAL SUCCESS 
AT ONE YEAR FOLLOWING RENAL 
ARTERY STENT PLACEMENT 
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Renal artery stent placement has become a common procedure to treat atherosclerotic 
renal artery stenosis (RAS). The usual indications for stent placement are drug resistant 
hypertension or renal function impairment. 
However, from clinical practice it is known that renal artery stenting may benefit some -
but not all - patients.'" To avoid unnecessary interventions, it is desirable to predict 
which patients will achieve long-term clinical success. To the best of our knowledge, 
however, such predictors for ciinical success of renal artery stent placement are scarcely 
available. 
The aim of the present study was, therefore, to identify pre-interventional parameters 
that may predict one-year clinical success after renal artery stent placement. We 
considered anatomical parameters of RAS obtained with angiography and intravascular 
ultrasound (IVUS) and functional parameters obtained by renal scintigraphy and renal 
vein blood sampling. 
METHODS 
Patients 
Forty consecutive patients (29 men, 11 women; aged 60±9.1 years [mean±SD]) were treated 
with stent placement for angiographically proven atherosclerotic RAS of more than 50% 
diameter reduction. For each patient the indication for intervention was recorded as 
hypertension and/or renal function impairment. Serum creatinine did not exceed 455 
pmol/I. All patients underwent renal scintigraphy and single-kidney renal function tests 
within one month before stent placement. Angiography and IVUS were performed at the 
time of stent placement. Medication regimen (in defined daily doses), blood pressure and 
serum creatinine were recorded from six months before intervention up to one-year 
follow-up. The following characteristics were recorded: age, sex, signs and symptoms of 
atherosclerotic vascular disease (angina pectoris, intermittent claudication, cerebrovascular 
disease or vascular surgery), duration of hypertension «2 or >2 years), smoking history 
(ever or never), obesity (body mass index >25 kg/m'), diabetes mellitus (absent or 
present) and serum creatinine concentration. The Local Committee Human Research 
approved the investigation. Written infonned consent was obtained from all patients. 
Definitions of treatment indication and clinical success 
Hypertension was defined as an averaged diastolic blood pressure >95 mmHg measured at 
two to four separate visits in the outpatient clinic from six months before intervention to 
the day of intervention. Renal function impairment was defined as an averaged serum 
creatinine >110 pmol/l measured in the six months period before intervention.' For 
determination of clinical success, averaged data on diastolic blood pressure and serum 
creatinine obtained in the period from six to twelve months follow-up were used. Clinical 
success at follow-up was defined as: 1. a normalization of diastolic blood pressure or a > 10 
mmHg decrease of diastolic blood pressure with the same or lower number of defined daily 
doses of antihypertensive medication' in patients treated for hypertension, 2. a 
normalization of serum creatinine values «110 pmol/l), or a >20% decrease of serum 
creatinine'·5.6 in patients treated for renal function impairment, and 3. a normalization of 
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diastolic blood pressure or a > 10 mmHg decrease of diastolic blood pressure with the same 
or lower number of defined daily doses of antihypertensive medications and/or a 
normalization of serum creatinine values «110 pmol/l), or a >20% decrease of serum 
creatinine in patients treated for both hypertension and renal function impairment. 
Renal scintigraphy 
Data derived from captopril enhanced renal scintigraphy were used to obtain information 
on the contribution of the affected and the contralateral kidneys to the total renal blood 
flow. Renal scintigraphy was performed with the patient in a supine position with the 
detector placed posteriorly. Patients received 25 or 50 mg of captopril orally at one hour 
before the examination. After intravenous administration of 74 MBq 99ffiTc-MAG" data were 
collected in 10-second frames during a 20-minute period. The number of total counts 
accumulated in the first 60 seconds were quantified and were taken as a measure of the 
renal blood flow to the affected and the contralateral kidneys. This method is based on the 
assumption that the early part of the time-activity curve is determined solely by the renal 
blood flow. The contribution of the renal blood flow of the individual kidneys to the total 
renal blood flow was recorded. Based on this value, we recorded whether the kidney to be 
stented had an abnormal contribution to the total renal blood flow. To account for normal 
variability in contribution of the individual kidneys, we defined abnormal contribution of 
the affected kidney as an affected kidney-to-two-kidney count ratio <0.45. 
Peripheral and renal vein blood sampling 
Concentrations of active renin and lllI-hippuran and 125I-thalamate in the left and right 
renal veins were measured and assayed as described by Wenting et at.' Constant infusions 
of lllI-hippuran and I25I-thalamate were given via an antecubital vein. After reaching the 
steady state, a renal venous blood sample was taken at each side simultaneously with a 
sample from the abdominal aorta. Samples from these sites were also used for renin 
measurements. Additional blood samples were taken at 15-minute intervals from a 
peripheral vein to estimate the total (two-kidney) clearances of IJII-hippuran and 
I15I-thalamate. All blood samples were immediately centrifuged and measurements were 
made in plasma. Determination of blood oxygen saturation served to assure that blood 
samples were taken from the renal veins. Single-kidney extraction ratios of ll'I-hippuran 
and 115I-thalamate were defined as (A-V)/A, where A = activity in the abdominal aorta and 
V = activity in renal vein. The total clearances of ll'I-hippuran and 125I-thalamate were 
taken as a measure of total effective renal plasma flow and glomerular filtration rate (GFR), 
respectively. The concentration of active renin in plasma was measured by 
radioimmunoassay.' We defined the vein-to-artery renin ratio of the affected side as 
'elevated' in case of values >1.48.' 
Stent placement procedure 
Pre-intervention digital subtraction angiograms were obtained using aortic-flush 
injections. The stenosis was then crossed with a 5F selective catheter and, if possible, 
pre-interventional IVUS was performed over a 0.020-in flexible tip guide wire (Boston 
Scientific). After predilation, angiography and IVUS were repeated. A Palmaz stent (type 
pl04, p154 or p204; Johnson & Johnson Interventional Systems, New York) was placed 
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whereby the stent sizing was based on the angiographic and IVUS findings. Stent 
placement was considered technically successful when angiography and IVUS showed 
complete stent-vessel wall apposition, complete lesion covering and <20% residual 
diameter stenosis." If necessary, additional stent dilatation was performed. During the 
procedure, the patients received 5,000 IU of heparin. Heparin infusion was continued for 
48 hours after the procedure (20,000-30,000 IU per day). Oral acetylsalicylic acid (100 mg 
daily) was started at the day of the procedure and continued during the entire follow-up 
period. 
Intravascular ultrasound 
For lVUS examination a 30 MHz mechanical imaging system with 4.3F catheters ("Princeps", 
Endosonies, Rijswijk, The Netherlands) was used." The lVUS catheter was positioned distally from 
the stenosis in a second-order renal artery branch. Real-time cross-sectional images of the main 
renal artery obtained during slow pullback of the lVUS catheter, were displayed on a monitor and 
stored on S-VHS videotape. Quantitative analysis on lumen, vessel and plaque area was perfonned at 
the most stenotic site and at a distal reference site in the main renal artery just before the first 
major side-branch. Previously we have described two lesion types in atherosclerotic RAS based on 
lVUS·criteria: one due to accumulation of atherosclerotic plaque with or without adaptive 
remodeling (adaptive remodeling lesion), and the other due to focal narrowing of the vessel wall 
without plaque accumulation (coarctation lesion)." Lesions in which RAS was considered to be 
caused by an adaptive remodeling lesion, had a larger vessel area at the target site than at the 
reference site (relative target to reference vessel area of >85%). Following the previously published 
definition, lesions were considered to be of the coarctation type when the relative target to 
reference vessel area was .5:85%. 
Data analysis 
The following parameters obtained inunediately prior to or at the time of stent placement were 
considered in the analysis: 
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Angiography: 
• percentage diameter stenosis 
Intravascular ultrasound: 
II Relative target to reference vessel area (coarctation vs. adaptive 
remodeling lesions) 
II Plaque area at the target site 
" Minimal stent lumen area after stent placement 
II Vessel area at the distal reference site 
Renal scintigraphy: 
.. Affected kidney-to-two-kidney countratio (abnormal or nonnal) 
peripheral and renal vein blood sampling: 
" Two-kidney glomerular filtration rate 
10 Extraction ratios of IlII-hippuran and l"l-thalamate of the affected kidney 
" Vein-to-artery renin ratio of the affected kidney (elevated or 
non-elevated) 
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All analyses were initially performed for the whole patient group and repeated for the 
subgroups of patients with hypertension and renal function impairment separately. 
Differences in baseline variables between patients with success or failure were assessed 
using the two·tailed chi· squared or Student's Hests where appropriate, at p=0.05. 
Univariate logistic regression analysis was used to determine which of the 
above-mentioned parameters was predictive for clinical success. For continuous variallles, 
the beta-coefficient was given and for categorical variables the odds ratio was computed. 
The variables that reached the significance level in the univariate regression analysis 
were subsequently entered in a multivariate model. Model selection was performed by a 
backward selection procedure. Data are presented as a proportion or as mean ± SD. All 
statistical analyses were performed using the SPSS software package for Windows, version 
9.0. 
RESULTS 
The indication for renal artery stent placement was hypertension in 14 patients, renal 
function impairment in 14, and hypertension combined with renal function impairment 
in 12 patients. Stent placement was technically successful in all patients. Clinical success 
was seen in 27/40 patients at one-year follow-up (Table 1). 
Table 1. Number of patients (n) with clinical success or failure 
according to their treatment indication. 
Success (n) Failure (n) 
Hypertension (n .. 14) 12 2 
Renal function impairment (n .. 14) 4 10 
Both (n=12) 11 
Hypertension 10 2 
Renal function impairment 5 7 
Of the 26 procedures performed for hypertension, 22 (85%) were considered clinically 
successful based on the predefined criteria, as were 9 of 26 procedures (35%) done for 
renal function impairment. Clinical success for hypertension was not influenced by the 
presence of renal function impairment (p=NS), but clinical success for renal function 
impairment was significantly influenced by the presence of hypertension (p=0.002). 
Comparison of baseline characteristics in patients with clinical success or failure showed 
that a lower serum creatinine at baseline was associated with clinical success at 
follow-up (116 ± 41.61'moljl vs. 209 ± 119.0, p=0.02; Table 2). 
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Table 2. Characteristics of patients with clinical success or failure one year after renal artery 
stent placement. 
Success 
n .. 27 
Age, years 58 ± 4.9 
Sex, % males 70 
Atherosclerotic vascular disease, % 81 
Recent onset of hypertension', % 37 
Ever smoked, % 85 
Obesity' ,% 48 
Diabetes meHitus, % 7 
Serum creatinine, pmollt 116±41.6 
Values are expressed as mean ± SD or proportions. 
* Chi-squared tests or Student's t-test where appropriate. 
t Onset of hypertension < 2 years before intervention. 
§ Body mass index ... 25 kg/m2, 
% Percentage. 
Failure 
n=13 p·value* 
62 ± 8,2 0.26 
77 0.66 
100 0.10 
23 0.38 
77 0.52 
54 0.74 
15 0.43 
209 ± 119.0 0.02 
In the whole group, regression analysis indicated a high two-kidney GFR as a statistically 
significant predictor of clinical success at one-year follow-up (p=0.03; Table 3). In 
addition, an abnormal affected kidney-to-two-kidney countratio and an elevated 
vein-to-artery renin ratio were borderline statistically significant predictors for one-year 
clinical success (p=0.058 for both). Neither angiographic nor IVUS parameters were 
predictive for clinical. Since only one parameter was significantly predictive for success, 
a multivariate analysis could not be performed. 
In the subgroup of patients treated for hypertension, there were no differences in 
baseline clinical characteristics between patients with and without clinical success. 
Regression analysis indicated the relative target to reference vessel area measured with 
Nus as a borderline significant predictor for clinical outcome, (p-coefficient (SE): 0.06 
(0.03); p=0.07). Patients with a clinically successful result after stent placement had a 
lower value of the target to reference vessel area (consistent with coarctation-type RAS 
lesions) than patients with clinical failure at follow-up (85% ± 23.4 vs. 121% ± 28.6, 
respectively). 
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In patients treated for renal function impairment, baseline serum creatinine was 
different between patients who had clinical success or failure; patients with clinical 
success had less impaired renal function at baseline (serum creatinine 139 ± 25.4 vs. 207 
± 98.2 jlmoljl, p=0.014). Regression analysis implicated an abnormal affected 
kidney-to-two-kidney countratio as a significant predictor for clinical success (odds 
ratio: 15; 95%-confidence interval: 1-218; p=0.048). An abnormal affected 
kidney-to-two-kidney countratio was present in 83% and 25% of the patients with 
clinical success and failure, respectively. 
Table 3. Data on pre-intervention parameters and regression coefficients of univariate logistic regression analysis 
predicting clinical success or failure one year following renal artery stent placement. 
Odds 
Success Failure p-Coeffident ratio 
n .. 27 n .. 13 (SE) (95% el) p 
Angiography 
Diameter stenosis, % 70 ± 14.1 67 ± 17.7 - 1.00 (2.34) 0.67 
Intravascular ultrasound 
Relative vessel area (target/reference), % 90 ± 24.0 95 ± 42,2 0.01 (0.01) 0.71 
Plaque area at the target site, mml 22 ± 9.1 19 ± 13.8 -0.03 (0.04) 0.47 
Lumen area in the stent, mm2 24 ± 4.3 25 ± 8.2 O.oJ (0.07) 0.62 
Reference vessel area, mml 39 ± 16,2 37 ± 13.0 -0.01 (0.03) 0.76 
Renal scintigraphy 
Abnormal affected kidney to two kidney 78 29 9(1-63) 0,06 
count ratio, % 
Peripheral renal vein blood sampUng 
Glomerular fittration rate, ml/min 71 ± 27.3 40 ± 13.2 - 0.08 (0.04) 0.03 
Extraction ratio of IlII-hippuran 0.46 ± 0.21 0.42 ± 0.18 -1.03 (2.16) 0.63 
Extraction ratio of mI_thatamate 0.13 ± 0.07 0.11 ± 0.05 -5.09 (7.17) 0.48 
Elevated vein-to-artery renin ratio of the 65 17 9 (1 - 95) 0.06 
affected kidney, % 
Values are means ± SD or proportions; GFR = Glomerular filtration rate; SE '" standard error; % = percentage. 
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DISCUSSION 
Previous studies have shown that, in terms of blood pressure and renal function, renal 
artery stent placement benefits some but not all patients. 1.2.13 An earlier study reported 
that, apart from the fact that the greatest improvement of systolic blood pressure 
occurred in patients with the highest baseline systolic blood pressure, there were no 
clinical parameters predictive for improvement of blood pressure and renal function." 
The present study investigated whether parameters derived from angiography, IVUS, 
renal scintigraphy and renal vein blood sampling could be used as predictors for one-year 
clinical outcome. 
As a first finding, our results showed a better clinical success at one-year follow-up in 
patients treated for hypertension than in patients treated for renal function impairment, 
with success rates of 85% and 35%, respectively. Although the results are critically 
dependent on the particular criteria to define clinical success in these subgroups, our 
results are in agreement with the previously reported findings of Blum et at.' for stent 
placement to treat hypertension and of White et al.1S for treatment of renal function 
impairment. 
In the whole patient group, a high serum creatinine and low GFR at baseline correlated 
with clinical failure of renal artery stenting at follow-up. This seems to echo the above 
mentioned finding of poorer outcome in patients treated for renal function impairment. 
However, even in the subgroup of patients treated for renal function impairment, a 
higher serum creatinine at baseline was associated with clinical failure. This finding 
corroborates the observation of others that clinical benefit of renal artery stent 
placement in patients with severe renal insufficiency is limited.' It seems, therefore, that 
treatment of RAS should preferably be performed before renal function becomes severely 
impaired. 
In patients treated for hypertension, we found no significant predictors of clinical 
success. However, the coarctation lesion type of RAS as determined with IVUS tended to 
be predictive at p=0.07. This lesion is characterized by a small relative vessel area at the 
target site. 
The ability to predict the clinical outcome of renal artery stent placement may be most 
desirable in the patients with renal function impairment, because clinical success was 
obtained in only 35% of the patients. An interesting finding was that the presence of an 
abnormal affected kidney-to-two-kidney countratio (lateralization) on the scintigram 
before stent placement emerged as a highly significant predictor of clinical success, 
particularly in the subgroup of patients treated for renal function impairment. Patients 
with lateralization on the scintigram had a 15-fold increased chance of having one-year 
clinical success. Since our scintigraphic data referred to the first 60 seconds after count 
detection, lateralization on the scintigram may reflect a difference in blood blood flow 
between the affected and contralateral kidney. This agrees with the finding that an 
elevated vein-to-artery renin ratio of the affected kidney was borderline predictive for 
clinical success; under steady state conditions, an increased vein-to-artery renin ratio of 
a kidney supplied by a stenosed artery is caused by decreased renal blood flow. 
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At first glance, the presence of lateratization to the affected kidney seems trivial, and a 
logical consequence of RAS. It should be pointed out, however, that RAS in our study 
was not associated with lateratization in all patients. This observation accords with 
results of Peters et aL" who measured renal blood flow with Technetium-99m-DTPA 
renography and found that 22-33% of the patients with RAS showed no evidence of 
decreased renal blood flow to the affected kidney. An alternative explanation may be 
that the absence of lateratization is related to the presence of bilateral RAS. However, 
bilateral RAS was present in only five patients in our study, two of whom did not have 
lateralization to the affected kidney. Decreased renal function at the so-called 
non-affected side could also have obscured the lateralization to the affected side. 
Interestingly, it has been reported earlier that success of revascularization was associated 
with a normal contralateral renal plasma flow as determined by measuring single-kidney 
clearances of p-aminohippurate after ureter catheterization.17 
Some limitations of the present study need to be addressed. First, the current results 
should be interpreted with caution, because of the limited size of our patient group. 
Second, as an estimate of renal blood flow, we measured the counts accumulated in the 
first 60 seconds after count detection on MAG,-scintigraphy, thereby ignoring that this 
part of the curve is also determined by the extraction ratios of the individual kidneys. 
But, irrespective of the exact physiological interpretation, the observation that this 
scintigraphic parameter may predict clinical success at one-year follow-up remains valid. 
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Although mud! has been published 
about stent plaO?ment for renal arlEly 
stenosis (RAS), little is known about 
the indirotionfor intervention and the 
mechanisms responsible for vessel 
patenry and diniwl outwme. !his 
thesis showed that revasmlarization of 
asymptomatic RAS is not necessary. 
In addition, we studied 38 ronsecutive 
patients with symptomatic RAS before 
stellt plaO?ment alld at one-year 
foIWw-up. Intravascular ultrasound 
shov.ro that RAS rould be due to 
plaque acrumu/ation or roaTdation. 
At jo/kJw-up, in·stent restenosis was 
due to plaque aa:umulation without 
stent rero,t 11 .. distal main renal 
artery shov.ro unexpected shrinkage 
(25%). Single-kidney function tests, 
on average, showed improvement in 
function of the treated kidney. 
Hypertension was suOO?SSfully treated 
in 85% of patients after stent 
plaO?ment but renalfunctional 
impairment in only 35';' In the latter 
patients, renal blood jWw data may 
sell'!? as predidor of dini",1 SUOO?SS. 
Chapter 11 
SUMMARY AND CONCLUSIONS 
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This thesis addresses several issues with regard to stent placement for renal artery 
stenosis (RAS). First, in Chapter 2, we retrospectively studied the natural history of 
incidentally found RAS in patients with peripheral vascular disease. To decide whether 
revascularization is necessary to prevent end-stage renal failure, patients with untreated 
asymptomatic RAS were studied during eight to ten years of follow-up. None of the 126 
patients with asymptomatic RAS developed end-stage renal failure or needed dialysis. 
Therefore, it seems that there is no clear indication for revascularization of RAS in these 
patients. 
Another issue of concern is that stent placement appears to benefit some - but not all -
patients treated for symptomatic RAS. Chapter 3 presents a review plus meta-analysis of 
studies on the effect of balloon angioplasty and stent placement for RAS. The results of 
this meta-analysis showed that stent placement was associated with a higher initial 
success rate and a lower restenosis rate than balloon angioplasty (98% vs. 77% and 17% 
vs. 26%, respectively). Based on this meta-analysis, the two treatment modalities were 
found to be roughly equivalent with regard to clinical success for blood pressure and 
renal function in approximately 60% and 70% of the patients, respectively. 
To identify vessel characteristics that may be responsible for success or failure of renal 
artery stent placement, Chapter 4 describes the morphology of renal arteries with and 
without stenosis as seen with IVUS. First, IVUS images obtained in renal artery specimens 
obtained at autopsy were validated with the corresponding histologic cross-sections. 
There was a good agreement between IVUS images and histologic findings for the 
assessment of renal artery lesions with or without calcifications. Second, and as a novel 
finding, quantitative analysis of IVUS images revealed that renal artery lumen narrowing 
could not only be caused by accumulation of atherosclerotic plaque (with or without 
adaptive remodeling), but also by focal narrowing of an otherwise normal renal arterial 
wall (coarctation). 
In Chapter 5 we assessed whether coarctation could be found clinically in patients with 
symptomatic RAS. Analysis of patients with symptomatic atherosclerotic RAS undergoing 
renal artery stent placement showed that coarctation lesions were responsible for the 
artery obstruction in about half of the patients. 
Chapter 6 describes the potential additional value of IVUS to enhance the technical 
quality of the procedure of stent placement. After predilatation a larger-sized balloon 
than suggested by angiography was selected for stent placement, based on the IVUS 
data. Even when a satisfactory angiographic end-result was obtained after stent 
placement, IVUS information prompted the interventionist to perform additional 
dilatation or additional stent placement in 33% of the patients studied. 
Chapter 7 presents a preliminary report on the behavior of stents placed in renal and 
femoropopliteal arteries assessed with IVUS. Lumen area reduction in renal artery stents 
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was solely due to accumulation of plaque. Lumen area reduction in femoropopliteal 
stents, however, was due to a combination of plaque accumulation and stent recoil. 
Chapter 8 describes the results of a serial study in a cohort of 38 consecutive patients 
undergoing renal artery stent placement using IVUS and angiography. Angiographic 
restenosis in the stent was present in 14% of the patients. Besides some plaque 
accumulation inside the stent seen with IVUS, a significant lumen area reduction was 
evidenced in the main renal artery distal to the stent, which was not caused by plaque 
accumulation but by a 25% decrease in vessel area. This shrinkage was confirmed by 
angiography and was limited to the ipsilateral main renal artery only. 
To better understand the origin of the heterogeneous clinical results after stent 
placement, it is useful to study the effect of stent placement on the function of the 
treated kidney in isolation. Since conventional renal function measurements do not 
provide this information, single-kidney function measurements were performed and are 
presented in Chapter 9. Prior to stent placement and at one-year follow-up, patients 
underwent selective renal vein blood sampling using a constant infusion method. After 
reaching the steady state, renal vein-to-artery renin ratios and extraction ratios of 
l3'I-hippuran (a measure for effective renal plasma flow; ERPF) and '''I-thalamate (a 
measure for glomerular filtration rate; GFR) of both the treated and the contralateral 
kidneys were measured. This, combined with renal blood flow measurements on renal 
scintigraphy, allowed determination of single-kidney renal plasma flow, ERPF and GFR. 
One-year after stent placement, the function of the treated kidney had, on average, 
significantly improved as shown by normalized vein-to-artery renin ratios, increased 
extraction ratios and increased single-kidney ERPF and GFR. 
To improve patient selection for renal artery stenting, Chapter 10 addresses an attempt 
to find pre-intervention parameters predictive for clinical success at one-year follow-up 
using regression analysis. Clinical success for blood pressure, using previously published 
definitions, was obtained in 85% of the hypertensive patients; for treatment of renal 
function impairment, success was obtained in 35% of patients. A high initial GFR 
emerged as a significant predictor for clinical success. Subgroup analysis showed that 
impaired contribution of the affected kidney to the total renal blood flow was predictive 
for success in patients treated for renal functional impairment. 
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE STUDIES 
From the present study it is concluded that asymptomatic RAS as an incidental finding 
in patients with peripheral vascular disease will seldomly lead to end-stage renal failure. 
Preventive revascularization seems, therefore, not necessary. 
With regard to morphology of symptomatic RAS, two forms of so-called 'atherosclerotic' 
RAS could be distinguished on the basis of our IVUS observations. The first was due to 
119 
Chapter 11 
plaque accumulation with or without adaptive remodeling, and the second to vessel 
coarctation without plaque accumulation. The etiology of this coarctation could not be 
determined in the present study. Since coarctation was also found in post-mortem renal 
arteries of asymptomatic subjects, further studies may use histologic sections and more 
specific staining techniques, e.g. to determine whether apoptosis is present in 
coarctation lesions. 
In our experience, IVUS used during renal artery stent placement provided additional 
information that led to adjunctive intervention in 33% of the procedures. Whether these 
additional interventions had a beneficial influence on the final technical or clinical 
outcome, was not addressed in the present work. To address this question, a randomized 
study comparing the results of stenting with and without the use of IVUS should be 
performed. 
At one-year follow-up IVUS showed some neointimal hyperplasia in the stent but no 
stent recoil. Remarkably, the renal artery distal to the stent, which had increased in size 
immediately after stent placement, at follow-up showed shrinkage without plaque 
accumulation. 
Single-kidney function measurements showed improvement in function of the treated 
kidney one year after stent placement. Clinical success of renal artery stent placement 
was obtained in 85% and 35% of the patients treated for hypertension and renal 
functional impairment, respectively. The lower success rate in patients with renal 
functional impairment seems to contradict the fact that stent placement, on average, 
improved the function of the treated kidney. Although the exact figures of clinical 
success are critically dependent on the definitions used, the observed functional 
improvement of the treated kidney may have too small an impact to result in 
improvement of the overall renal function. We attempted to identify predictors of 
clinical success of renal artery stenting, which is especially important in patients treated 
for renal functional impairment. Data on renal blood flow, derived from the inflow curve 
of MAG,-scintigraphy, appeared to be predictive for clinical success in patients treated 
for renal functional impairment. The renal blood flow data, however, should be 
interpreted with caution and the conclusions of the study should be prospectively tested 
in future studies. 
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A/h""""l er vee! gesdJreven is over 
stent-plaatsing bij nierarterie-stenose, is 
er nog llrinig bekend over indiruties 
voor behande/ing en de Judore1l die het 
uiteindelijke resultaat bepa/en. In dit 
proejsdlrijt IWrd aangetoond dat revas-
ruiarisatie van nierartene.stenose bij 
asymptamatisd!e patienten llrinig 
zinwl is. Daamaast bestudeerden lve 
38 patienten met symptomatisd!e 
nierarten'e-stenose voorafgaand aan 
stent-plaatsing en na eenjaar. 
Intmvasru/aire edlOgrajie toonde aan 
dat een nierarterie-stenDSe kan rn:>rden 
veroO/zoakt door plaque-ophoping of 
door coordatie. Vemauwing van het 
lwnen van de stent na een jaw VIQS 
enke/ het gevalg van plaqlle-ophoping. 
Daamaast viel op dat de nieran/ene 
aansluitend aan de stent verldeind \\t1S 
met 25% Gemiddeld gezien leidde 
stent-plaatsing tot een verbetering van 
de fundie van de behandelde nier. 
Klinisd! sucres lverd behaald bij 85% 
van de patienten met hypertensie en in 
35% van de patienten met nieljundie-
stoomissen. Hij patienten behandeld 
vanlWge nieljundiestoomissen 
kunnen bloedstroommetingen mogelijk 
het Idinisd! sucres voompellen. 
Hoofdstuk 12 
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In dit proefschrift worden resultaten gepresenteerd met betrekking tot onderzoek naar 
stent-plaatsing als behandeling van patHinten met een nierarterie-stenose (d.L 
vernauwing van de nierslagader). Ais eerste staan in Hoofdstuk 2 de resultaten van een 
retrospectief onderzoek naar het natuurlijk beloop van de bij toeval gevonden 
nierarterie-stenose bij patienten met perifeer vaatlijden beschreven. Om te kunnen 
beslissen of revascularisatie nodig is ter voorkoming van nierfalen, werden 126 patienten 
met asymptomatische nierarterie-stenose gedurende een periode van acht tot tien jaar 
gevolgd. Geen van deze patienten bleek in aanmerking te komen voor nierdialyse. Er lijkt 
dus geen indicatie te bestaan voor de revascularisatie van nierarterie-stenosen bij deze 
groep patienten. 
Een ander belangrijk onderwerp betreft het feit dat niet aile patienten met 
symptomatische nierarterie-stenose op de lange termijn baat hebben bij stent-plaatsing. 
Hoofdstuk 3 presenteert een overzicht en een meta-analyse van studies inzake het effect 
van ballon-angioplastiek en stent-plaatsing als behandeling van patienten met een 
nierarterie-stenose. De resultaten van de meta-analyse toonden aan dat stent-plaatsing 
een hoger technisch succespercentage had en een lager percentage restenose (d.L 
hervernauwing) dan ballon-angioplastiek (respectievelijk 98% versus 77%, en 17% versus 
26%). Uit de meta-analyse bleek verder dat de twee behandelingsmethodes ongeveer 
gelijk waren voor wat betreft het klinisch succes t.a.v. bloeddruk en nierfunctie (in 
ongeveer 60% en 70% van de patiEinten). 
Om vaatwandeigenschappen te identificeren, die verantwoordelijk kunnen zijn voor 
succes of falen van stent-plaatsing voor nierarterie-stenose, werd de morfologie van 
nierarterien met en zonder stenose bestudeerd met behulp van intravasculaire echografie 
(IVUS) en beschreven in Hoofdstuk 4. Eerst werden de IVUS-beelden van nierarterien, 
verkregen bij obductie, vergeleken met de bijbehorende histologische coupes. Bij 
kwalitatieve analyse bleek er overeenstemming te zijn tussen IVUS en histologie voor wat 
betreft het detecteren van plaques met of zander kalk. Kwantitatieve analyse van de 
IVUS-beelden toonde aan dat vernauwingen van de nierarterie niet aileen veroorzaakt 
konden worden door een ophoping van atherosclerotische plaque in de vaatwand (al dan 
niet met compensatoire vergroting van de vaatwand), maar ook door een lokale 
vaatwandvernauwing van een verder normale nierarterie (coarctatie). Deze laatste 
bevinding was nieuw, en tot dusver niet beschreven. 
In Hoofdstuk 5 wordt beschreven of coaretatie ook klinisch gevonden kon worden bij 
patienten met nierarterie-stenose. Analyse van IVUS-beelden, verkregen bij 
symptomatische patienten met nierarterie-stenose voorafgaand aan stent-plaatsing, liet 
zien dat coaretatie verantwoordelijk was voor de obstructie bij ongeveer de helft van de 
patienten. 
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Hoofdstuk 6 beschriift de mogeliik additionele waarde van IVUS am de technische 
kwaliteit van de plaatsing van een stent bii patienten met een nierarterie-stenose te 
verbeteren. Na predilatatie werden op basis van IVUS-informatie grotere ballonnen 
gebruikt voor stent-plaatsing dan no dig leek op het angiogram. Zelfs wal1neer de 
stent-plaatsing angiografisch succesvol was, werd op basis van de IVUS informatie bii 
33% van de patienten een extra dilatatie of stent-plaatsing uitgevoerd. 
In Hoofdstuk 7 geeft een beschriiving van onderzoek m.b.v. IVUS naar het mechanisme 
dat verantwoordeliik was voor de verkleining van het lumen (d.L doorstroomopening) 
van stents in nier - en femoropopliteale arterien in de tiid. Het lumen van stents in de 
nierarterie werd kleiner als gevolg van plaque-ophoping. Verkleining van het lumen in 
femoropopliteale stents, daarentegen, werd veroorzaakt door een combinatie van 
plaque-ophoping en een verkleining van de stent. 
In Hoofdstuk 8 staan de resultaten beschreven van een onderzoek in een groep van 38 
patienten die stent-plaatsing in de nierarterie ondergingen en die na een iaar weer 
onderzocht werden met behulp van IVUS en angiografie. Angiografische restenose in de 
stent was aanwezig in 14% van de patienten. Met IVUS werd vastgesteld dat, naast een 
geringe ophoping van plaque in de stent, het lumen van de nierarterie stroomafwaarts 
van de stent significant verkleind was. Dit laatste werd niet veroorzaakt door 
plaque-ophoping maar door een verkleining van de vaatwand zelf met 25%. Dit werd 
bevestigd door angiografie en bleek beperkt te ziin tot de hoofdtak van de behandelde 
nierarterie. 
Om de oorzaak van de verschillen in klinisch resultaat na stent-plaatsing beter te kunnen 
begriipen, is het van belang am het effect van stent-plaatsing op de behandelde nier zelf 
te bestuderen. Omdat de conventionele nierfunctie bepalingen deze informatie niet 
kunnen geven, werden gescheiden nierfunctie bepalingen uitgevoerd. De resultaten 
hiervan ziin beschreven in Hoofdstuk 9. Voorafgaand aan stent-plaatsing en een iaar 
daarna werden na toediening van van de stoffen Il!I-hippuran en "'I-thalamaat, 
bloedmonsters afgenomen uit de niervene en -arterie van beide nieren afzonderliik. Uit 
deze bloedmonsters werd de renine ratio (veneus/arterieel) bepaald, samen met de 
extractie-ratio's van 1l1I-hippuran (een maat voor de effectieve nierdoorstroming; ERPF) 
en van l"I-thalamaat (een maat voor de glomerulaire filtratie snelheid; GFR) van zowel 
de behandelde als de contralaterale nier. Dit - gecombineerd met bloedstroommetingen, 
afkomstig van nierscintigrafie - maakte het mogeliik am de gescheiden ERPF en GFR te 
berekenen. Gemiddeld genomen was de functie van de behandelde nier een iaar na 
stent-plaatsing verbeterd. Dit bleek uit genormaliseerde renine-ratio's, verhoogde 
extractie-ratio's en verbetering van de ERPF en GFR van de behandelde nier. 
Om de selectie van patienten voor stent-plaatsing van nierarterie-stenose te verbeteren, 
werd in Hoofdstuk 10 beschreven in hoeverre parameters, voorafgaand aan de interventie 
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verkregen, het klinisch succes na een iaar konden voorspellen. Hiertoe werd gebruik 
gemaakt van regressie-analyse. Klinisch succes t.a.v. bloeddruk, gedefinieerd naar 
aanleiding van eerder gepubticeerde criteria, werd verkregen in 85% van de patienten 
met hypertensie; het klinisch succes t.a.v. nierfunctie was 35% bii patienten met 
nierfunctiestoornissen. Een hoge GFR was een significante voorspeHer van ktinisch 
succes. Analyse in subgroepen toonde aan dat een beperkte biidrage van de te 
behandelen nier aan de totale bloedstroom voorspeHend was voor klinisch succes bii 
patienten met nierfunctiestoornissen. 
CONCLUSIES EN AANBEVELINGEN VOOR VERDER ONDERZOEK 
Uit deze studie kan worden geconcludeerd dat de asymptomatische nierarterie-stenose, 
die bii toeval gevonden wordt bii patienten met perifeer vaattijden, zelden zal leiden tot 
eind-stadium nierfalen. Preventieve revascularisatie voor deze groep patienten is daarom 
niet geindiceerd. 
Wat betreft de morfologie van symptomatische nierarterie-stenose, werden op basis van 
de IVUS observaties twee vormen van zogenaamde "atherosclerotische" 
nierarterie-stenose onderscheiden. De eerste was het gevolg van plaque-ophoping, al dan 
niet met compensatoire vergroting van de vaatwand. De tweede was het gevolg van 
coarctatie zonder plaque-ophoping. De oorzaak van coarctatie kon in dit onderzoek niet 
worden vastgesteld. Omdat coarctatie ook aanwezig was in nierarterien verkregen bii 
obductie, zou in verder onderzoek histologie gebruikt kunnen worden met specifieke 
kleuringstechnieken, biivoorbeeld om te onderzoeken of apoptose (d.L geprogrammeerde 
celdood) aanwezig is bii de nierarterie-stenoses veroorzaakt door coarctatie. 
Uit onze ervaring met het gebruik van IVUS tijdens stent-plaatsing bleek dat de 
verkregen additionele informatie aanleiding gaf tot extra interventie in 33% van de 
procedures. Of deze extra interventies een positieve invloed hadden op het uiteindeliike 
technische en klinische resultaat, kon niet worden· vastgesteld. Het antwoord op deze 
vraag kan aHeen volgen uit een gerandorniseerde studie waarin de resultaten van 
stent-plaatsing met en zonder gebruik van IVUS worden vergeleken. 
Een iaar na stent-plaatsing tiet IVUS enige plaque-ophoping zien in de stent, maar geen 
verkleining van de stent zelf. OpvaHend genoeg was het nierarterie-segment 
stroomatwaarts van de stent na een iaar significant kleiner geworden door krimp van de 
vaatwand zonder plaque-ophoping. 
Gescheiden nierfunctie bepalingen toonden een verbetering aan van de functie van de 
behandelde nier een iaar na stent-plaatsing. Ktinisch succes werd behaald bii 85% van de 
patienten met hypertensie en in 35% van de patienten met nierfunctiestoornissen. Het 
beperkte succes bii patienten met nierfunctiestoornissen tiikt de constatering dat 
stent-plaatsing, gerniddeld gezien, leidt tot een verbetering van de functie van de 
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behandelde nier, tegen te spreken. Alhoewel de klinische succespercentages sterk 
afhankelijk zijn van de gebruikte definities, zou het best zo kunnen zijn dat de 
verbetering in functie van de behandelde nier te weinig bijdraagt om een verbetering van 
de totale nierfunctie te bewerkstelligen in de patienten behandeld met het doel om de 
nierfunctie te stabiliseren of te verbeteren. Onze poging om predictors voor klinisch 
succes van stent-plaatsing te vinden, is uiteraard speciaal van belang bij de 
laatstgenoemde groep patienten met nierfuntiestoornissen. Bloedstroommetingen op de 
inflow-curve van het MAG,-scintigram bleken voorspeUend te zijn voor klinisch succes, in 
het bijzonder bij patienten behandeld voor nierfunctiestoornissen. Deze 
bloedstroommetingen moeten echter behoedzaam worden geinterpreteerd en de 
conclusies van deze analyse moeten prospectief worden getest in verder onderzoek. 
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